US20240000748A1 - Formulations and methods for treating acute cannabinoid overdose - Google Patents
Formulations and methods for treating acute cannabinoid overdose Download PDFInfo
- Publication number
- US20240000748A1 US20240000748A1 US18/253,025 US202118253025A US2024000748A1 US 20240000748 A1 US20240000748 A1 US 20240000748A1 US 202118253025 A US202118253025 A US 202118253025A US 2024000748 A1 US2024000748 A1 US 2024000748A1
- Authority
- US
- United States
- Prior art keywords
- inhibitor
- cannabinoid
- alkyl
- carboxamide
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 343
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 343
- 238000000034 method Methods 0.000 title claims abstract description 197
- 239000000203 mixture Substances 0.000 title claims description 82
- 230000001154 acute effect Effects 0.000 title claims description 47
- 238000009472 formulation Methods 0.000 title description 51
- 239000003112 inhibitor Substances 0.000 claims abstract description 256
- 206010033296 Overdoses Diseases 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 208000003870 Drug Overdose Diseases 0.000 claims abstract description 41
- 231100000725 drug overdose Toxicity 0.000 claims abstract description 41
- 208000024891 symptom Diseases 0.000 claims abstract description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 36
- 229960004242 dronabinol Drugs 0.000 claims description 33
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 30
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 230000036470 plasma concentration Effects 0.000 claims description 29
- 229920000858 Cyclodextrin Polymers 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 22
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 22
- 229950011318 cannabidiol Drugs 0.000 claims description 22
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 22
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- 238000007920 subcutaneous administration Methods 0.000 claims description 18
- 238000012544 monitoring process Methods 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 239000003401 opiate antagonist Substances 0.000 claims description 14
- 239000007972 injectable composition Substances 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 238000002405 diagnostic procedure Methods 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 238000007918 intramuscular administration Methods 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 238000009534 blood test Methods 0.000 claims description 9
- 208000025517 cannabinoid hyperemesis syndrome Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 239000000829 suppository Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000004001 thioalkyl group Chemical group 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 239000002249 anxiolytic agent Substances 0.000 claims description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- 239000002895 emetic Substances 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 5
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 4
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical group C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 claims description 4
- 229960004381 flumazenil Drugs 0.000 claims description 4
- 229960004127 naloxone Drugs 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000002262 irrigation Effects 0.000 claims description 3
- 238000003973 irrigation Methods 0.000 claims description 3
- 238000009117 preventive therapy Methods 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- BNLYOVHLLDBOFZ-LJQANCHMSA-N n-tert-butyl-3-[(r)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical group C1N(C(=O)NC(C)(C)C)CC1O[C@@H](C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 BNLYOVHLLDBOFZ-LJQANCHMSA-N 0.000 abstract description 49
- 239000005557 antagonist Substances 0.000 abstract description 17
- 239000000556 agonist Substances 0.000 abstract description 11
- 230000007935 neutral effect Effects 0.000 abstract description 7
- PVXOUGHWLCBJOW-UHFFFAOYSA-N azetidine-1-carboxamide Chemical compound NC(=O)N1CCC1 PVXOUGHWLCBJOW-UHFFFAOYSA-N 0.000 description 62
- 150000001875 compounds Chemical class 0.000 description 57
- -1 isooxazolyl Chemical group 0.000 description 41
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 239000013543 active substance Substances 0.000 description 28
- 229940124802 CB1 antagonist Drugs 0.000 description 18
- 229940065144 cannabinoids Drugs 0.000 description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 18
- 239000002904 solvent Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 229920002988 biodegradable polymer Polymers 0.000 description 10
- 239000004621 biodegradable polymer Substances 0.000 description 10
- 229920001432 poly(L-lactide) Polymers 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 229960004853 betadex Drugs 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 8
- 239000001116 FEMA 4028 Substances 0.000 description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000218236 Cannabis Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 229940125425 inverse agonist Drugs 0.000 description 7
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 6
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical group CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 6
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000005829 chemical entities Chemical class 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 4
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 4
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 4
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 4
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 4
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 4
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical group Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 4
- 229960003015 rimonabant Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- QLYKJCMUNUWAGO-GAJHUEQPSA-N Taranabant Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=C(C=CC=1)C#N)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-GAJHUEQPSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000004964 sulfoalkyl group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229950005022 taranabant Drugs 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- AXJQVVLKUYCICH-OAQYLSRUSA-N (4s)-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1C([C@H](C1)C=2C=CC=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-OAQYLSRUSA-N 0.000 description 2
- ZPNWJGPRXXTUNI-UHFFFAOYSA-N 1-(1h-indol-2-yl)-2-phenylethanone Chemical class C=1C2=CC=CC=C2NC=1C(=O)CC1=CC=CC=C1 ZPNWJGPRXXTUNI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000027559 Appetite disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- DLHLOYYQQGSXCC-DOFZRALJSA-N O-Arachidonoyl ethanolamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCN DLHLOYYQQGSXCC-DOFZRALJSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- IQQBRKLVEALROM-UHFFFAOYSA-N drinabant Chemical compound C=1C(F)=CC(F)=CC=1N(S(=O)(=O)C)C(C1)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 IQQBRKLVEALROM-UHFFFAOYSA-N 0.000 description 2
- 229950010628 drinabant Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229950011100 ibipinabant Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- FFLSJIQJQKDDCM-UHFFFAOYSA-N jwh-250 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)CC1=CC=CC=C1OC FFLSJIQJQKDDCM-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000003887 narcotic antagonist Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- UNAZAADNBYXMIV-UHFFFAOYSA-N otenabant Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 UNAZAADNBYXMIV-UHFFFAOYSA-N 0.000 description 2
- 229950005009 otenabant Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- KSLCYQTUSSEGPT-UHFFFAOYSA-N (2-iodophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone Chemical compound CN1CCCCC1CN1C2=CC=CC=C2C(C(=O)C=2C(=CC=CC=2)I)=C1 KSLCYQTUSSEGPT-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- AXTADRUCVAUCRS-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrole-2,5-dione Chemical compound OCCN1C(=O)C=CC1=O AXTADRUCVAUCRS-UHFFFAOYSA-N 0.000 description 1
- DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 description 1
- SZQZAUQREUIIJH-UHFFFAOYSA-N 1h-indol-2-yl(naphthalen-1-yl)methanone Chemical class C1=CC=C2C(C(C=3NC4=CC=CC=C4C=3)=O)=CC=CC2=C1 SZQZAUQREUIIJH-UHFFFAOYSA-N 0.000 description 1
- RLGAYEJPGHIHIB-UHFFFAOYSA-N 1h-indol-2-yl(phenyl)methanone Chemical class C=1C2=CC=CC=C2NC=1C(=O)C1=CC=CC=C1 RLGAYEJPGHIHIB-UHFFFAOYSA-N 0.000 description 1
- XETLOFNELZCXMX-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(4-hexoxyphenyl)-2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C1=CC(OCCCCCC)=CC=C1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 XETLOFNELZCXMX-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HNMJDLVMIUDJNH-MJGOQNOKSA-N 2-[(1r,3s)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCCC)=CC=C1[C@H]1C[C@@H](O)CCC1 HNMJDLVMIUDJNH-MJGOQNOKSA-N 0.000 description 1
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical group CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- VLAWOMHNZSYXBG-UHFFFAOYSA-N 2-benzylazetidine-1-carboxamide Chemical compound NC(=O)N1CCC1CC1=CC=CC=C1 VLAWOMHNZSYXBG-UHFFFAOYSA-N 0.000 description 1
- MVRPPTGLVPEMPI-UHFFFAOYSA-N 2-cyclohexylphenol Chemical class OC1=CC=CC=C1C1CCCCC1 MVRPPTGLVPEMPI-UHFFFAOYSA-N 0.000 description 1
- FTHTUFXEOVWCBY-UHFFFAOYSA-N 2-cyclopropyl-3,4,5,6-tetramethyl-1H-indole Chemical class N1C2=CC(C)=C(C)C(C)=C2C(C)=C1C1CC1 FTHTUFXEOVWCBY-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical class CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- NMQMVJQRTFTBRP-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(1-phenylpropyl)azetidine-1-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)N(C1)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 NMQMVJQRTFTBRP-UHFFFAOYSA-N 0.000 description 1
- HUDXUJAUMGZRTM-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC2OC3=CC=CC=C3OC2)C1 HUDXUJAUMGZRTM-UHFFFAOYSA-N 0.000 description 1
- FQRXPJWEIQPYDB-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(2,4,4-trimethylpentan-2-yl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)CC(C)(C)C)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 FQRXPJWEIQPYDB-UHFFFAOYSA-N 0.000 description 1
- LAXPNMTYJFUPLS-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(2-methylbutan-2-yl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)CC)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 LAXPNMTYJFUPLS-UHFFFAOYSA-N 0.000 description 1
- UTUQLLRCOGHGNA-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(2-thiophen-2-ylethyl)azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCCC=2SC=CC=2)C1 UTUQLLRCOGHGNA-UHFFFAOYSA-N 0.000 description 1
- METUDFXYNOQTNR-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(3-ethoxypropyl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NCCCOCC)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 METUDFXYNOQTNR-UHFFFAOYSA-N 0.000 description 1
- ZEFIHOYEBVFJHP-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(cyclopropylmethyl)azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC2CC2)C1 ZEFIHOYEBVFJHP-UHFFFAOYSA-N 0.000 description 1
- ANQULCLSJHDFPW-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(furan-2-ylmethyl)azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC=2OC=CC=2)C1 ANQULCLSJHDFPW-UHFFFAOYSA-N 0.000 description 1
- VXLHWSJMIIVPLQ-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(oxolan-2-ylmethyl)azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC2OCCC2)C1 VXLHWSJMIIVPLQ-UHFFFAOYSA-N 0.000 description 1
- BGJNROJQOIWLDR-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(thiophen-3-ylmethyl)azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC2=CSC=C2)C1 BGJNROJQOIWLDR-UHFFFAOYSA-N 0.000 description 1
- PEPGMGNTJDNZLZ-SMFUYQKNSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-[(1r)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide Chemical compound COC1=CC=CC([C@@H](C)NC(=O)N2CC(C2)OC(C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)=C1 PEPGMGNTJDNZLZ-SMFUYQKNSA-N 0.000 description 1
- PEPGMGNTJDNZLZ-LFUZPPSTSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-[(1s)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide Chemical compound COC1=CC=CC([C@H](C)NC(=O)N2CC(C2)OC(C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)=C1 PEPGMGNTJDNZLZ-LFUZPPSTSA-N 0.000 description 1
- LXWFPZFBKVAOKJ-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-[(2,5-dimethylfuran-3-yl)methyl]azetidine-1-carboxamide Chemical compound O1C(C)=CC(CNC(=O)N2CC(C2)OC(C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)=C1C LXWFPZFBKVAOKJ-UHFFFAOYSA-N 0.000 description 1
- WWSIDXRHPVNWKU-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-[(2-methoxyphenyl)methyl]azetidine-1-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)N1CC(OC(C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)C1 WWSIDXRHPVNWKU-UHFFFAOYSA-N 0.000 description 1
- CCEFOLOUCQAPIP-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-[(5-methyl-1,2-oxazol-3-yl)methyl]azetidine-1-carboxamide Chemical compound O1C(C)=CC(CNC(=O)N2CC(C2)OC(C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)=N1 CCEFOLOUCQAPIP-UHFFFAOYSA-N 0.000 description 1
- PTVKXSFBTUPKHX-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-tert-butylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Br)C=C1F PTVKXSFBTUPKHX-UHFFFAOYSA-N 0.000 description 1
- UOUVSTIOFTVFBW-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-(2,4,4-trimethylpentan-2-yl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)CC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 UOUVSTIOFTVFBW-UHFFFAOYSA-N 0.000 description 1
- OCHYTDGJJAJMCX-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-(2-methylbutan-2-yl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 OCHYTDGJJAJMCX-UHFFFAOYSA-N 0.000 description 1
- SXKYOXHYTLPEKN-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-cyclohexylazetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC2CCCCC2)C1 SXKYOXHYTLPEKN-UHFFFAOYSA-N 0.000 description 1
- QMSUBBRVMTUXLK-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-cyclopentylazetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC2CCCC2)C1 QMSUBBRVMTUXLK-UHFFFAOYSA-N 0.000 description 1
- AOWUZRSEDDBIEQ-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-ethylazetidine-1-carboxamide Chemical compound C1N(C(=O)NCC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 AOWUZRSEDDBIEQ-UHFFFAOYSA-N 0.000 description 1
- HWLAWTMTIUBMRV-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-prop-2-enylazetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NCC=C)C1 HWLAWTMTIUBMRV-UHFFFAOYSA-N 0.000 description 1
- PDHLIKUPUVAAMF-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 PDHLIKUPUVAAMF-UHFFFAOYSA-N 0.000 description 1
- MUZSHPIDCIYXKA-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-propylazetidine-1-carboxamide Chemical compound C1N(C(=O)NCCC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 MUZSHPIDCIYXKA-UHFFFAOYSA-N 0.000 description 1
- MSOLSOQZIQEGTJ-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]-n-cyclohexylazetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC2CCCCC2)C1 MSOLSOQZIQEGTJ-UHFFFAOYSA-N 0.000 description 1
- ZRPZKPOIUVRRNV-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC(F)=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 ZRPZKPOIUVRRNV-UHFFFAOYSA-N 0.000 description 1
- UVKBYKCMWRKXFC-UHFFFAOYSA-N 3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(F)C=C1 UVKBYKCMWRKXFC-UHFFFAOYSA-N 0.000 description 1
- KZCORNNBNPIOCD-UHFFFAOYSA-N 3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC(C)C)C1 KZCORNNBNPIOCD-UHFFFAOYSA-N 0.000 description 1
- LSJZXKGOYIYDQD-UHFFFAOYSA-N 3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]-n-prop-2-enylazetidine-1-carboxamide Chemical compound C1=CC(OC(F)F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NCC=C)C1 LSJZXKGOYIYDQD-UHFFFAOYSA-N 0.000 description 1
- WMDFBQORZPFSTC-UHFFFAOYSA-N 3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)F)C=C1 WMDFBQORZPFSTC-UHFFFAOYSA-N 0.000 description 1
- JAUAKLMPZRBOAT-UHFFFAOYSA-N 3-[bis(4-bromophenyl)methoxy]-n-tert-butylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 JAUAKLMPZRBOAT-UHFFFAOYSA-N 0.000 description 1
- LXUJLLMJXCJOKU-UHFFFAOYSA-N 3-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=CC=C1 LXUJLLMJXCJOKU-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HMXDWDSNPRNUKI-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide Chemical group CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JDNLPKCAXICMBW-UHFFFAOYSA-N JWH 018 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=CC=C12 JDNLPKCAXICMBW-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920000383 Poly(ethylene glycol) methyl ether-block-poly(D,L lactide) Polymers 0.000 description 1
- 229920000437 Poly(lactide-co-caprolactone)-block-poly(ethylene glycol)-block-poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000451 Polycaprolactone-block-polytetrahydrofuran-block-polycaprolactone Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000458 Polyglycolide-block-poly(ethylene glycol)-block-polyglycolide Polymers 0.000 description 1
- 229920000432 Polylactide-block-poly(ethylene glycol)-block-polylactide Polymers 0.000 description 1
- 229920000387 Polypyrrole-block-poly(caprolactone) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- SQNNHEYXAJPPKH-UHFFFAOYSA-N chloroethene;prop-2-enoic acid Chemical class ClC=C.OC(=O)C=C SQNNHEYXAJPPKH-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- ZDEVQOADMXOMDO-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 ZDEVQOADMXOMDO-UHFFFAOYSA-N 0.000 description 1
- PZIOEWGGOWVPEF-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-methoxyphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 PZIOEWGGOWVPEF-UHFFFAOYSA-N 0.000 description 1
- WJBNQPICTCHOQS-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-methylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 WJBNQPICTCHOQS-UHFFFAOYSA-N 0.000 description 1
- CENFVFWZOPWHSC-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 CENFVFWZOPWHSC-UHFFFAOYSA-N 0.000 description 1
- XHSUIMMWJMJPLV-UHFFFAOYSA-N n-(1-adamantyl)-3-[bis(2-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound ClC1=CC=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 XHSUIMMWJMJPLV-UHFFFAOYSA-N 0.000 description 1
- OFRJJEMHDBIYAL-UHFFFAOYSA-N n-(1-adamantyl)-3-[bis(4-bromophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1=CC(Br)=CC=C1C(C=1C=CC(Br)=CC=1)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 OFRJJEMHDBIYAL-UHFFFAOYSA-N 0.000 description 1
- PLJCQPPJAJEHHX-UHFFFAOYSA-N n-(1-adamantyl)-3-[bis(4-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 PLJCQPPJAJEHHX-UHFFFAOYSA-N 0.000 description 1
- KJRUZQCAADTPFK-UHFFFAOYSA-N n-[(2-bromothiophen-3-yl)methyl]-3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC2=C(SC=C2)Br)C1 KJRUZQCAADTPFK-UHFFFAOYSA-N 0.000 description 1
- HVLBCOMCWMHADX-QMRFKDRMSA-N n-[(2r)-butan-2-yl]-3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)N[C@H](C)CC)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 HVLBCOMCWMHADX-QMRFKDRMSA-N 0.000 description 1
- VGZODVVTKYTELC-UHFFFAOYSA-N n-benzyl-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NCC=2C=CC=CC=2)C1 VGZODVVTKYTELC-UHFFFAOYSA-N 0.000 description 1
- AYFRSZYMSBZIOY-UHFFFAOYSA-N n-benzyl-3-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC=CC=1)OC1CN(C(=O)NCC=2C=CC=CC=2)C1 AYFRSZYMSBZIOY-UHFFFAOYSA-N 0.000 description 1
- BAMHKCNSETUOBO-UHFFFAOYSA-N n-butan-2-yl-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 BAMHKCNSETUOBO-UHFFFAOYSA-N 0.000 description 1
- CKUZPZFYFGZOSU-UHFFFAOYSA-N n-butan-2-yl-3-[(4-chlorophenyl)-[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC(F)=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 CKUZPZFYFGZOSU-UHFFFAOYSA-N 0.000 description 1
- OGDZECLEZAVEGM-UHFFFAOYSA-N n-butan-2-yl-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(F)C=C1 OGDZECLEZAVEGM-UHFFFAOYSA-N 0.000 description 1
- PQQGOZKVEOKNQU-UHFFFAOYSA-N n-butan-2-yl-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(SC)C=C1 PQQGOZKVEOKNQU-UHFFFAOYSA-N 0.000 description 1
- BMSHUEMPIVDLSO-UHFFFAOYSA-N n-butan-2-yl-3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)F)C=C1 BMSHUEMPIVDLSO-UHFFFAOYSA-N 0.000 description 1
- SZTJHJQPGRWWOH-UHFFFAOYSA-N n-butan-2-yl-3-[[4-(trifluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)(F)F)C=C1 SZTJHJQPGRWWOH-UHFFFAOYSA-N 0.000 description 1
- BHSWRGGHCFTVNO-UHFFFAOYSA-N n-butan-2-yl-3-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=CC=C1 BHSWRGGHCFTVNO-UHFFFAOYSA-N 0.000 description 1
- AMPJXPAFTWUKMF-UHFFFAOYSA-N n-butyl-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NCCCC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 AMPJXPAFTWUKMF-UHFFFAOYSA-N 0.000 description 1
- MPZMPPJJGNTVHR-UHFFFAOYSA-N n-cyclohexyl-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC2CCCCC2)C1 MPZMPPJJGNTVHR-UHFFFAOYSA-N 0.000 description 1
- UJOARMFZGDVVQP-UHFFFAOYSA-N n-cyclohexyl-3-[(4-methylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC2CCCCC2)C1 UJOARMFZGDVVQP-UHFFFAOYSA-N 0.000 description 1
- ORJHHJOWGFPRHF-UHFFFAOYSA-N n-cyclohexyl-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC2CCCCC2)C1 ORJHHJOWGFPRHF-UHFFFAOYSA-N 0.000 description 1
- AHAYYOYPIVITNU-UHFFFAOYSA-N n-cyclohexyl-3-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC=CC=1)OC1CN(C(=O)NC2CCCCC2)C1 AHAYYOYPIVITNU-UHFFFAOYSA-N 0.000 description 1
- IEFNRZMZYCIABF-UHFFFAOYSA-N n-propan-2-yl-3-[[4-(trifluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)(F)F)C=C1 IEFNRZMZYCIABF-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MLFSLFJODRKRDN-UHFFFAOYSA-N n-tert-butyl-3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 MLFSLFJODRKRDN-UHFFFAOYSA-N 0.000 description 1
- UYLKXPAIMKBQON-UHFFFAOYSA-N n-tert-butyl-3-[(2-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=CC=C1F UYLKXPAIMKBQON-UHFFFAOYSA-N 0.000 description 1
- NAQXOHUKTAFNDO-UHFFFAOYSA-N n-tert-butyl-3-[(4-chlorophenyl)-(2,4-dichlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC(Cl)=CC=1)Cl)C1=CC=C(Cl)C=C1 NAQXOHUKTAFNDO-UHFFFAOYSA-N 0.000 description 1
- BNLYOVHLLDBOFZ-UHFFFAOYSA-N n-tert-butyl-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 BNLYOVHLLDBOFZ-UHFFFAOYSA-N 0.000 description 1
- QLFCAMOXLZVIQX-UHFFFAOYSA-N n-tert-butyl-3-[(4-chlorophenyl)-[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC(F)=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 QLFCAMOXLZVIQX-UHFFFAOYSA-N 0.000 description 1
- MBCVORKWWTUQEI-UHFFFAOYSA-N n-tert-butyl-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(F)C=C1 MBCVORKWWTUQEI-UHFFFAOYSA-N 0.000 description 1
- IKANRRQTBDVMDU-UHFFFAOYSA-N n-tert-butyl-3-[(4-methoxyphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC(C)(C)C)C1 IKANRRQTBDVMDU-UHFFFAOYSA-N 0.000 description 1
- NCZIGNURHCMRNY-UHFFFAOYSA-N n-tert-butyl-3-[(4-methylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC(C)(C)C)C1 NCZIGNURHCMRNY-UHFFFAOYSA-N 0.000 description 1
- OFSKFPDEPXQBGO-UHFFFAOYSA-N n-tert-butyl-3-[[2-fluoro-4-(piperidine-1-carbonyl)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(C(=O)N2CCCCC2)C=C1F OFSKFPDEPXQBGO-UHFFFAOYSA-N 0.000 description 1
- JTUXDFJRCBYXNX-UHFFFAOYSA-N n-tert-butyl-3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)F)C=C1 JTUXDFJRCBYXNX-UHFFFAOYSA-N 0.000 description 1
- DCBWYROPEMAPBJ-UHFFFAOYSA-N n-tert-butyl-3-[[4-(trifluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)(F)F)C=C1 DCBWYROPEMAPBJ-UHFFFAOYSA-N 0.000 description 1
- NMVHPPLPCPNGLX-UHFFFAOYSA-N n-tert-butyl-3-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=CC=C1 NMVHPPLPCPNGLX-UHFFFAOYSA-N 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960005250 naloxone hydrochloride Drugs 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- ACLUUJWYNUJGGO-UHFFFAOYSA-N naphthalen-1-yl(1h-pyrrol-2-yl)methanone Chemical class C=1C=CC2=CC=CC=C2C=1C(=O)C1=CC=CN1 ACLUUJWYNUJGGO-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229920004905 octoxynol-10 Polymers 0.000 description 1
- 229920004914 octoxynol-40 Polymers 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000779 poly(divinylbenzene) Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001855 polyketal Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 208000026961 psychosexual disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- JTESKNWFQRABFY-UHFFFAOYSA-M sodium;tetracosyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCCCCCCCOS([O-])(=O)=O JTESKNWFQRABFY-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229950003174 surinabant Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
Definitions
- THC A9-tetrahydrocannabinol
- SCs synthetic cannabinoids
- FIG. 1 illustrates a plot of the effect of ANEB-001 on THC-induced hypolocomotion in mice. The total active time is plotted against conditions of vehicle only, treatment with THC, and treatment with ANEB-001 and THC.
- veh vehicle; THC: tetrahydrocannabinol.
- FIG. 2 illustrates a plot of a single ascending oral dose study in humans of ANEB-001. Plasma concentrations (ng/mL) of ANEB-001 are plotted against time.
- compositions, formulations, methods, and devices for treating THC and SC overdose are Described herein.
- the overdose is an acute overdose.
- methods described herein comprise use of a CB1 inhibitor.
- compositions, formulations, and methods for reversing the symptoms of cannabinoid overdose using the CB1 antagonist ANEB-001, or a salt, adjunct, or polymorph thereof are described below or throughout this specification.
- a pharmaceutical composition comprising a CB1 inhibitor comprising administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has a known or suspected acute drug overdose reaction.
- methods of using a pharmaceutical composition comprising a CB1 inhibitor the method comprising administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has a known or suspected acute drug overdose reaction, wherein the CB1 inhibitor has the structure of formula (I):
- R 1 and R 2 are independently selected from a group of formula (II):
- R 4 , R 5 , and R 6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, NR 14 C(O)R 19 , NR 14 SO 2 R 20 , COOR 19 , OC(O)R 20 , CONR 13 R 14 and SO 2 NR 13 R 14 , R 13 and R 14 are independently selected from hydrogen and alkyl or form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O, and S; R 19 is selected from H, alkyl, aryl and heteroaryl, and R 20 is selected from alkyl, aryl and heteroaryl.
- R 4 , R 5 , and R 6 are chloro or trifluoromethyl. Further provided herein are methods wherein the patient shows signs of an acute cannabinoid overdose. Further provided herein are methods wherein the patient shows signs of cannabinoid hyperemesis syndrome. Further provided herein are methods wherein the method comprises treatment for drug overdose prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic. Further provided herein are methods wherein the prior treatment comprises one or more of orogastric lavage or whole bowel irrigation.
- the method further comprises a diagnostic test prior to treatment with the CB1 inhibitor.
- the diagnostic test is a blood test.
- the patient has a cannabinoid plasma concentration of at least 50 ⁇ g/L.
- the patient has a cannabinoid plasma concentration of at least 100 ⁇ g/L.
- the patient has a cannabinoid plasma concentration of 50 ⁇ g/L to 300 ⁇ g/L.
- the pharmaceutical composition is prepared as an oral, sublingual, buccal, rectal, nasal, or parenteral dose.
- CB1 inhibitor is cannabigerol, ibipinabant, otenabant, tetrahydrocannabivarin, virodhamine, rimonabant, or taranabant. Further provided herein are methods wherein the CB1 inhibitor has the structure:
- the dose of the CB1 inhibitor is 1 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 25 mg to 200 mg. Further provided herein are methods wherein the CB1 inhibitor is formulated as an oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, suppository, or intranasal administration. Further provided herein are methods wherein further comprising administering a pharmaceutically acceptable alkaline agent. Further provided herein are methods wherein the pharmaceutical composition is formulated to deliver an effective dose of the CB1 inhibitor in no more than 10 min.
- the dose of the CB1 inhibitor or pharmaceutical composition thereof is 50 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor or pharmaceutical composition thereof delivers a therapeutically effective amount of the CB1 inhibitor in no more than 10 minutes. Further provided herein are methods wherein the dose of the CB1 inhibitor or pharmaceutical composition thereof delivers a therapeutically effective amount of the CB1 inhibitor in no more than 5 minutes. Further provided herein are methods wherein the amount of the CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. Further provided herein are methods wherein the amount of the CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration.
- methods wherein the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 min. Further provided herein are methods wherein the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour.
- methods of using a CB1 inhibitor as a pre-exposure prophylactic therapy comprising administering an effective amount of the CB1 inhibitor prior to exposure to a cannabinoid. Further provided herein are methods wherein the cannabinoid is tetrahydrocannabinol.
- CB1 inhibitor is formulated for oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, suppository, or intranasal administration. Further provided herein are methods wherein the CB1 inhibitor has the structure:
- kits for treating a patient suspected of a drug overdose comprising administering an effective amount of a CB1 inhibitor to a patient and monitoring the patient for reduced symptoms associated with overdose. Further provided herein are methods wherein monitoring comprises monitoring heart rate or respiration. Further provided herein are methods wherein the CB1 inhibitor has the structure:
- injectable compositions for treating a suspected drug overdose comprising a CB1 inhibitor, an opioid antagonist, and a benzodiazepine antagonist.
- the benzodiazepine antagonist is flumazenil.
- the opioid antagonist is naloxone.
- the injectable composition is formulated in a single dose injectable device.
- the CB1 inhibitor has the structure
- compositions for treating a suspected drug overdose comprising a CB1 inhibitor and an anxiolytic agent.
- anxiolytic agent is a cannabinoid.
- cannabinoid is cannabidiol.
- composition is formulated for intranasal delivery.
- CB1 inhibitor has the structure
- a pharmaceutical composition comprising a CB1 inhibitor
- the method comprising orally administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has an acute drug overdose reaction, wherein the CB1 inhibitor has the structure:
- the dose of the CB1 inhibitor is 50 mg to 300 mg, and wherein the amount of CB1 inhibitor in the bloodstream of the patient reaches at least 200 ng/mL within one hour after oral administration.
- the patient shows signs of an acute cannabinoid overdose.
- the acute cannabinoid overdose is caused by a compound from the Cannabis genus.
- the acute cannabinoid overdose is caused by a synthetic cannabinoid.
- the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids.
- methods wherein the patient shows signs of cannabinoid hyperemesis syndrome Further provided herein are methods wherein the method further comprises treatment for drug overdose prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic. Further provided herein are methods wherein the method further comprises a diagnostic test prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the diagnostic test is a blood test. Further provided herein are methods wherein the patient has a cannabinoid plasma concentration of at least 50 ⁇ g/L.
- the patient has a cannabinoid plasma concentration of 50 ⁇ g/L to 300 ⁇ g/L.
- the dose of the CB1 inhibitor is 50 mg to 200 mg.
- the dose of the CB1 inhibitor is 75 mg to 200 mg.
- the CB1 inhibitor has the structure:
- compositions, formulations, and methods for reversing cannabinoid overdose and/or one or more symptoms thereof comprising administering a CB1 inhibitor in an amount sufficient to reduce the severity of one or more overdose symptoms or reverse the cannabinoid overdose in a patient.
- fast-acting formulations comprising CB1 inhibitors for emergency/rescue applications.
- formulations comprising combinations of CB1 inhibitors and other active agents.
- compositions, formulations, and methods described herein may comprise use of a CB1 inhibitor.
- the CB1 inhibitor is a CB1 antagonist.
- the CB1 inhibitor is a CB1 inverse agonist.
- the CB1 inhibitor is a CB1 neutral antagonist. Certain embodiments include the use of the CB1 antagonist and a specific cannabinoid antagonist.
- R 1 and/or R 2 is substituted with 1 to 3 substituents. In some embodiments, R 1 and/or R 2 is substituted with 1 or 2 substituents. In one embodiment, R 1 and R 2 are independently selected from a group —A(R 4 )(R 5 )(R 6 ), where A is an aryl or heteroaryl ring, and where A may be selected from phenyl, naphthyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, pyridyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl and isobenzofuryl.
- one of Rand R 2 is aryl and the other is heteroaryl, or both R 1 and R 2 are aryl. In some embodiments, both R 1 and R 2 are monocyclic.
- R 4 , R 5 , and R 6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, NR 14 C(O)R 19 , NR 14 SO 2 R 20 , COOR 19 , OC(O)R 20 , CONR 13 R 14 and SO 2 NR 13 R 14 , wherein R 13 and R 14 are independently selected from hydrogen and alkyl or may form a 5 or 6 membered ring optionally containing 1 or 2 additional hetero
- R 1 and R 2 may be the same or different, and in one embodiment are different.
- R 3 is NR 9 R 10 .
- R 3 is NR 9 R 10 , and R 9 and R 10 are independently lower alkyl or hydrogen.
- Y is C ⁇ 0.
- Y is C ⁇ 0 and R 3 is NR 9 R 10 .
- R 3 is NR 9 R 10 , R 9 is lower alkyl, and R 10 is hydrogen.
- halo group is fluoro, chloro, bromo or iodo. In some embodiments, the halo group is chloro or bromo. In some embodiments, R 4 , R 5 , and R 6 are selected from alkyl, thioalkyl, alkoxy and alkylsulfonyl. In some embodiments, R 4 , R 5 , and R 6 are selected from lower alkyl. In some embodiments, R 4 , R 5 , and R 6 are selected from methyl and ethyl.
- R 4 , R 5 , and R 6 are selected from haloalkyl
- the alkyl is in some embodiments methyl, and the R 4 , R 5 , or R 6 group is trifluoromethyl.
- R 4 , R 5 , and R 6 are selected from haloalkoxy
- the alkyl is in some embodiments methyl and the R 4 , R 5 , or R 6 group is trifluoromethoxy or difluoromethoxy.
- one or two of R 4 , R 5 , and R 6 are hydrogen.
- at least one of the R 1 and R 2 groups has a non-hydrogen substituent in the ortho-position(s) relative to the point of attachment to the [—CH—O—] group.
- the R 1 or R 2 groups may independently have one or two non-hydrogen substituents in said ortho position(s).
- Preferred ortho-substituents include halo and haloalkyl, as described herein. In some embodiments, ortho-substituents are chloro and trifluoromethyl.
- R 1 and/or R 2 is selected from heteroaryl; and/or m and/or n is 2; and/or R 11 and/or R 12 is lower alkyl.
- R 1 and/or R 2 is selected from aryl, and m and n are 1.
- the ring is 6-membered.
- the ring is saturated or partially saturated.
- additional heteroatoms such as N and O. In some embodiments, there are 0 or 1 additional heteroatoms.
- R 1 is selected from aryl.
- R 2 is selected from aryl or heteroaryl.
- R 3 is selected from NR 9 R 10 .
- R 3 is selected from alkyl, aryl and heteroaryl.
- Y is selected from C ⁇ 0, C ⁇ S and SO 2 . Where Y is selected from (CR 7 R) p , then R 7 and/or R 8 in some embodiments are hydrogen or methyl, and p is 1 or 2. Where Y is SO 2 , R 3 is in some embodiments selected from alkyl, aryl and heteroaryl.
- R 9 is selected from piperidinyl (such as 1-piperidinyl) and morpholinyl (such as 4-morpholinyl).
- R 9 is cyclic, such as aryl or heteroaryl, and the R 9 group may be substituted with one or more substituent groups.
- R 9 is substituted with halo, nitro, or alkoxy haloalkyl.
- the ring formed by NR 9 R 10 may be substituted, and substituents include hydroxy, methoxy, mono- and di-alkyl amino and alkoxycarbonyl.
- R 9 is selected from aryl, heteroaryl and a non-aromatic heterocyclic group, and R 10 is selected from H and lower alkyl.
- R 9 is selected from alkyl and R 10 is selected from lower alkyl.
- R 9 and R 10 form a 4, 5, 6, or 7-membered ring, or a 5, 6, or 7-membered ring, optionally containing an additional heteroatom selected from N and 0.
- m is 1 and/or n is 1. In some embodiments, both m and n are 1. Where m is 2, the R 11 groups may be the same or different, but at least one of the R 11 groups in the (CHR 11 ) 2 moiety is hydrogen. Where n is 2, the R 2 groups may be the same or different, but at least one and optionally both of the R 12 groups in the (CHR 12 ) 2 moiety is/are hydrogen. In some embodiments, R 11 and R 12 are independently selected from hydrogen and methyl. In some embodiments, at least one of R 11 and R 12 is hydrogen. In some embodiments, R 15 is selected from alkyl, such as lower alkyl (substituted or unsubstituted).
- R 15 is selected from aryl, such as phenyl (substituted or unsubstituted). In one embodiment, R 15 is selected from lower alkyl, benzyl and phenyl. In some embodiments, R 16 is hydrogen. In some embodiments, R 17 is lower alkyl, aryl, or heteroaryl, and in one embodiment is aryl.
- R 1 and R 2 are independently selected from substituted or unsubstituted phenyl or naphthyl. In some embodiments, R 1 and R 2 are independently selected from phenyl or naphthyl having 1 to 3 substituents. In one embodiment the substituent groups are selected from halogen and haloalkyl. In some embodiments, R 1 and R 2 are selected from mono-cyclic aromatic groups.
- R 1 and R 2 are independently selected from a group of formula (II):
- the groups R 1 and R 2 in are the same or different, and in one embodiment are different.
- R 4 , R 5 , and R 6 are selected from halo
- the halo group is in some embodiments fluoro, chloro, bromo or iodo.
- R 4 , R 5 and R 6 are selected from alkyl, thioalkyl, alkoxy and alkylsulfonyl
- the alkyl is in some embodiments lower alkyl.
- R 4 , R 5 , and R 6 are selected from aminoalkyl, alkylaminoalkyl and dialkylaminoalkyl
- the alkyl is selected from methyl and ethyl.
- R 4 , R 5 , and R 6 are selected from dialkylaminoalkyl
- the dialkylamino fragment is in some embodiments selected from cyclicamino, such as morpholino and piperazino.
- R 4 , R 5 , and R 6 are selected from haloalkyl
- the alkyl is in some embodiments methyl
- the R 4 , R 5 , or R 6 group is trifluoromethyl.
- R 4 , R 5 , and R 6 are selected from haloalkoxy
- the alkyl is in some embodiments methyl and the R 4 , R 5 , or R 6 group is selected from trifluoromethoxy or difluoromethoxy.
- R 4 , R 5 , and R 6 are hydrogen. At least one of the R 1 and R 2 groups has a non-hydrogen substituent in the ortho-position(s).
- the R 1 or R 2 groups in some embodiments independently have one or two non-hydrogen substituents in the ortho position(s) relative to the point of attachment to the [—CH—O—] group.
- Preferred ortho-substituents include halo and haloalkyl, as described herein. In some embodiments, ortho-substituents are chloro and trifluoromethyl.
- R 13 and R 14 form a 5- or 6-membered ring, the ring in some embodiments is 6-membered. Where the ring contains additional heteroatoms, in some embodiments, these are N and/or O. In some embodiments, there are 0 or 1 additional heteroatoms.
- R 13 and R 14 are independently hydrogen or alkyl.
- R 9 is selected from hydrogen or alkyl. In some embodiments, R 9 is alkyl. In some embodiments, R 9 is selected from methyl, ethyl, propyl, sec-butyl, or tert-butyl.
- the alkyl group in some embodiments are substituted or unsubstituted, and in one embodiment is substituted. In some embodiments, one or two substituent groups are present. In some embodiments, substituents are hydroxy, alkoxy, thioalkyl, amino, mono- and dialkyl amino, alkoxycarbonyl, aryl, and heterocyclic groups including both heteroaryl and non-aromatic heterocyclic groups.
- R 9 is an acyclic alkyl group, in some embodiments it is substituted by a cyclic alkyl group; and where R 9 is a cyclic alkyl group in some embodiments it is substituted by an acyclic alkyl group.
- the substituent group is heteroaryl, in some embodiments the heteroaryl is a 5- or 6-membered ring containing one or more N, O, or S atoms, such as thiophenyl, furanyl, isoxazolyl, thiazolyl and benzothiophenyl.
- substituent groups in some embodiments include dihydrobenzofuranyl, dihydrobenzodioxinyl, tetrahydrofuranyl, pyrrolidinyl, oxopyrrolindyl and benzodioxolyl.
- R 3 has the structure:
- m is 0 or 1 or 2. In some embodiments, m is 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1 and m is 1. In one embodiment, at least one or two of R 10 , R 11 , and R 12 are selected from hydrogen. In a further embodiment, at least two of R 10 , R 11 , and R 12 are selected from methyl. In a further embodiment, R 9 is selected from cyclic alkyl, including cyclopentyl, cyclohexyl, norbornanyl and adamantyl. In some embodiments, R 9 groups are tertiary butyl, sec-butyl, isobutyl, isopropyl, n-propyl and ethyl.
- the CB1 antagonist of Formula (I) or (Ia) is ((R)-(+)-N-tert-butyl-3-[(4-chloro)phenyl-(2-trifluoromethyl)phenyl]methoxyazetidine-1-carboxamide (Compound ANEB-001). In some embodiments, the CB1 antagonist is ((S)-( ⁇ )-N-tert-butyl-3-[(4-chloro)phenyl-(2-trifluoromethyl)phenyl]methoxyazetidine-1-carboxamide.
- the CB1 antagonist is (N-tert-butyl-3-[(4-chloro)phenyl-(2-trifluoromethyl)phenyl]methoxyazetidine-1-carboxamide.
- the CB1 antagonist is Cannabigerol.
- the CB1 antagonist is ibipinabant.
- the CB1 antagonist is otenabant.
- the CB1 antagonist is tetrahydrocannabivarin.
- the CB1 antagonist is virodhamine.
- the CB1 inverse agonist is rimonabant.
- the CB1 inverse agonist is taranabant. In some embodiments, the CB1 inverse agonist is surinabant or drinabant. In some embodiments, a composition or formulation described herein comprises two or more CB1 inhibitors. In some embodiments, the CB1 inhibitor is a neutral antagonist. In some instances, the CB1 inhibitors comprise one or more substitutions at the phenyl groups that function as effective neutral antagonists of CB1.
- a CB1 inhibitor comprises a structure of formula (Ia), wherein R 1 and R 2 are substituted aromatic groups, and R 3 is an optionally substituted C 1 -C 6 alkyl group.
- R 3 is tert-butyl.
- R 3 is isopropyl.
- R 3 is sec-butyl.
- R 1 is a substituted aromatic group.
- R 1 is an optionally substituted phenyl group.
- R 1 is a phenyl group substituted with a halogen (e.g., F, Cl, Br, I).
- R 1 is a phenyl group substituted with Cl.
- R 1 is a phenyl group para substituted in (4-position) with a halogen (e.g., F, Cl, Br, I). In some instances, R 1 is a 4-chlorophenyl group.
- R 2 is a substituted aromatic group. In some instances, R 2 is an optionally substituted phenyl group. In some instances, R 2 is a phenyl group substituted with a C 1 -C 5 alkyl group. In some instances, R 2 is a phenyl group substituted with a C 1 -C 5 trifluoroalkyl group. In some instances, R 2 is a phenyl group substituted with a trifluoromethyl group.
- R 2 is a phenyl group ortho substituted in (4-position) with a C 1 -C 5 trifluoroalkyl group. In some instances, R 2 is a 2-trifluoromethylphenyl group.
- the CB1 inhibitor is compound ANEB-001, having the following structure:
- the CB1 inhibitor has the structure:
- the CB1 inhibitor has the structure:
- a CB1 inhibitor is a compound of Table 1.
- Formulations described herein may comprise a CB1 inhibitor and one or more excipients.
- described herein is a CB1 inhibitor co-formulated or co-administered with one or more agents that alkalinizes the tissues or body fluids in contact with the drug when disbursed.
- the CB1 inhibitor is ANEB-001.
- a buccal delivery or sublingual delivery is in some instances particularly useful for this aspect of the methods described herein.
- alkalinizing the solution in some instances resulting in the absorption of a CB1 inhibitor is hastened as the nitrogen in a CB1 inhibitor is less likely to exist in the protonated state, where the protonated state reduces its ability to traverse biologic membranes.
- an alkaline formulation in combination with a CB1 inhibitor treatment in some instances facilitates the improved and faster absorption of the compound, especially in buccal or sublingual delivery.
- combinations of a CB1 inhibitor with appropriate alkalinizing compounds can either modify the protonation of a CB1 inhibitor or modify the buccal or sublingual tissue to promote improved transmission of a CB1 inhibitor into the bloodstream.
- surfactants including sodium dodecyl (lauryl) sulfate, polysorbates, laureths, Brijs, and benzalkonium chloride are predominantly water-soluble compounds that form associations (micelles) in aqueous solution. These associations in some instances enhance the sublingual or transbuccal permeation of a CB1 inhibitor into the bloodstream.
- the active compound may be used in a pharmaceutical formulation including a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier comprising a compound or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
- the carrier(s) is “acceptable” in the sense of being compatible with the other ingredients of the formulation, the activity of the CB1 inhibitor, and not deleterious to the patient. Proper formulation is dependent upon the route of administration chosen.
- compositions of the CB1 inhibitors described herein may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- the formulations for CB1 inhibitors include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, suppository or rectal, and topical (including dermal, buccal, sublingual and intraocular) administration, although the most suitable route may depend upon the condition and disorder of the patient. In some instances, such formulations reverse one or more overdose symptoms.
- the method comprises using a composition formulated for oral, sublingual, intranasal, absorbed by suppository, or parenteral administration comprising an effective amount of a CB1 inhibitor or a salt or polymorph thereof that is effective to reverse cannabinoid overdose or one or more symptoms of overdose in a patient.
- formulations are fast-acting to reverse or ameliorate an overdose, such as in an emergency or rescue situation.
- fast-acting formulations include methods of administration which deliver an effective amount of a formulation comprising a CB1 inhibitor to the bloodstream in a rapid manner.
- a formulation is delivered in effective concentrations in no more than 1 hr, 30 min, 15 min, 10 min, 5 min, 2 min, 1 min, 30 sec or no more than 15 sec. In some instances, a formulation is delivered in effective concentrations in 10 sec-2 hr, 30 sec-2 hr, 1 min-2 hr, 10 sec-30 sec, 10 sec-1 min, 10-sec-2 min, or 15 min-2 hr. In some instances, a fast-acting formulation is delivered via intranasal, rectal, buccal, inhalation, or transdermal routes.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound described herein (e.g., CB1 inhibitor) or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- the carrier is a biopolymer, such as methyl cellulose.
- Formulations of CB1 inhibitors described herein for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- the a CB1 inhibitor compound can be a powder or granules, a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water liquid emulsion, or a water-in-oil liquid emulsion.
- a CB1 inhibitor may also be used as a bolus, electuary or paste.
- compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricants, surface active agents or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Dragee cores are provided with suitable coatings.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions may take the form of tablets, lozenges, pastilles, or gels formulated in a conventional manner ( Remington: The Science and Practice of Pharmacy , Twenty Second Edition, Pharmaceutical Press, 2015).
- Such compositions may comprise the active ingredient in a flavored basis such as with sucrose or other sweetener, and/or acceptable flavorings.
- Pharmaceutically acceptable carriers for formulations described herein (e.g., with a CB1 inhibitor) may comprise one or more polymers.
- the pharmaceutically acceptable carrier is a polymer.
- Examples of polymers suitable for oral, buccal, intranasal, transdermal, thin-film, suppository or other administration include biocompatible and biodegradable polymers.
- biocompatible polymers include natural or synthetic polymers such as polystyrene, polylactic acid, polyketal, butadiene styrene, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, polyalkylcyanoacrylate, styrene-maleic anhydride copolymer, polyvinyl acetate, polyvinylpyridine, polydivinylbenzene, polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, polycaprolactone, poly(alkyl cyanoacrylates), poly(lactic-co-glycolic acid), and the like.
- natural or synthetic polymers such as polystyrene, polylactic acid, polyketal, butadiene styrene, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, polyalkylcyan
- the carrier is Labrasol. In some instances, the carrier is methyl cellulose.
- the pharmaceutically acceptable carrier comprises one or more biodegradable polymers.
- biodegradable polymers provide the advantages of using a formulation that will eventually disintegrate, which facilitates release of the benzofuran compound and elimination of the carrier in vivo.
- benzofuran compounds can also be released from the matrix of non-biodegradable polymers as a result of gradual efflux from channels within the polymer matrix, including those formed by soluble materials included in the polymer matrix.
- biodegradable polymers include polylactide polymers include poly(D, L-lactide)s; poly(lactide-co-glycolide) (PLGA) copolymers; polyglycolide (PGA) and polydioxanone; caprolactone polymers; chitosan; hydroxybutyric acids; polyanhydrides and polyesters; polyphosphazenes; and polyphosphoesters.
- the biodegradable polymer for use in the nanoparticles is poly-(D,L-lactide-co-glycolide).
- Functionalized poly (D,L-lactide)s can also be used as biodegradable polymers in the nanoparticles described herein.
- Examples of functionalized poly(D,L-lactide)s include poly(L-lactide), acrylate terminated; poly(L-lactide), amine terminated; poly(L-lactide), azide terminated; poly(L-lactide), 2-bromoisobutyryl terminated; poly(L-lactide), 2-bromoisobutyryl terminated; poly(L-lactide) 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentonate; poly(L-lactide)N-2-hydroxyethylmaleimide terminated; poly(L-lactide) 2-hydroxyethyl, methacrylate terminated; poly(L-lactide), propargyl terminated; or poly(L-lactide), thiol terminated.
- AB-31-eblock copolymers such as poly(ethylene glycol) methyl ether-block-poly(D,L-lactide); poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) PEG; poly(ethylene glycol)-block-poly(.epsilon.-caprolactone) methyl ether PEG; and polypyrrole-block-poly(caprolactone).
- biodegradable polymers include ABA triblock copolymers such as polylactide-block-poly(ethylene glycol)-block-polylactide PLA; poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide); poly(lactide-co-caprolactone)-block-poly(ethylene glycol)-block-poly(lactide-co-caprolactone); polycaprolactone-block-polytetrahydrofuran-block-polycaprolactone; and polyglycolide-block-poly(ethylene glycol)-block-polyglycolide PEG.
- ABA triblock copolymers such as polylactide-block-poly(ethylene glycol)-block-polylactide PLA; poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide); poly(
- Biodegradable polymers also include various natural polymers.
- natural polymers include polypeptides including those modified non-peptide components, such as saccharide chains and lipids; nucleotides; sugar-based biopolymers such as polysaccharides; cellulose; carbohydrates and starches; dextrans; lignins; polyamino acids; adhesion proteins; lipids and phospholipids (e.g., phosphorylcholine).
- the polymer is a cellulose derivative such as hydroxypropyl methylcellulose polymers. Hydroxypropyl methyl cellulose (HPMC) is a non-ionic cellulose ether made through a series of chemical processes, with the natural polymer cellulose as the raw material.
- HPMC Hydroxypropyl methyl cellulose
- HPMC non-ionic cellulose ether in the shape of white powder, odorless and tasteless.
- HPMC is also known as hypromellose, is a methylcellulose modified with a small amount of propylene glycol ether groups attached to the anhydroglucose of the cellulose.
- Useful pharmaceutical compositions also, optionally, include solubilizing agents to aid in the solubility of a CB1 inhibitor described herein.
- the term “solubilizing agent” generally includes agents that result in formation of a micellar solution or a true solution of the agent.
- Certain acceptable nonionic surfactants for example polysorbate 80, are useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.
- the solubilizing agent can be selected from the group consisting of a cyclodextrin, a glycol, a glycerol, and combinations thereof. In some embodiments, the solubilizing agent includes a cyclodextrin.
- the solubilizing agent can be selected from the group consisting of a ⁇ -cyclodextrin derivative, a ⁇ -cyclodextrin, and combinations thereof.
- the solubilizing agent includes a hydroxy alkyl- ⁇ -cyclodextrin.
- the solubilizing agent can include a ⁇ -cyclodextrin selected from the group consisting of a hydroxy alkyl- ⁇ -cyclodextrin, a sulfoalkyl ether- ⁇ -cyclodextrin, and combinations thereof.
- the solubilizing agent includes hydroxypropyl- ⁇ -cyclodextrin.
- the cyclodextrin can include an ⁇ -cyclodextrin, ⁇ -cyclodextrin derivative, a ⁇ -cyclodextrin derivative, a ⁇ -cyclodextrin, or a combination derivative thereof.
- the solubilizing agent can include a cyclodextrin.
- the solubilizing agent can include a ⁇ -cyclodextrin derivative, a ⁇ -cyclodextrin, or a mixture thereof.
- the solubilizing agent can include a hydroxy alkyl- ⁇ -cyclodextrin.
- the solubilizing agent includes a ⁇ -cyclodextrin including at least one of a hydroxy alkyl- ⁇ -cyclodextrin (e.g., hydroxypropyl- ⁇ -cyclodextrin) or a sulfoalkyl ether- ⁇ -cyclodextrin (e.g., sulfobutyl ether- ⁇ -cyclodextrin).
- the liquid the solubilizing agent can include hydroxypropyl- ⁇ -cyclodextrin.
- the cyclodextrin is CAVASOL® W7 HP (hydroxypropyl- ⁇ -cyclodextrin).
- the cyclodextrin is KLEPTOSE® HP (hydroxypropyl- ⁇ -cyclodextrin). In some embodiments, the cyclodextrin is CAVAMAX® W7 ( ⁇ -cyclodextrin). In some embodiments, the cyclodextrin is CAPTISOL® (sulfoalkyl ether- ⁇ -cyclodextrin). In some embodiments, the cyclodextrin is CAVASOL® W7 M (methyl- ⁇ -cyclodextrin). In some embodiments, the cyclodextrin is CAVASOL® W8 HP (hydroxypropyl- ⁇ -cyclodextrin). In some embodiments, the cyclodextrin is CAVAMAX® W8 ( ⁇ -cyclodextrin). In some embodiments, the cyclodextrin is CAVAMAX® W6 ( ⁇ -cyclodextrin).
- useful pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
- acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
- bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane
- buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
- acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
- compositions also, optionally, include one or more salts in an amount required to bring osmolality of the composition into an acceptable range.
- salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
- compositions include one or more surfactants to enhance physical stability or for other purposes.
- Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
- the CB1 inhibitors as described herein are formulated into an injectable composition.
- the injectable composition comprises a CB1 inhibitor, or the pharmaceutical composition described herein, an opioid antagonist, and a benzodiazepine antagonist.
- the benzodiazepine antagonist is flumazenil.
- the opioid antagonist is naloxone or naltrexone.
- the injectable composition is formulated in a single dose injectable device.
- CB1 inhibitors described herein may be formulated with one or more pharmaceutically active agents.
- the CB1 inhibitor is formulated with naloxone or an opioid antidote.
- an opioid antidote or opioid antagonist includes nalmefene or nalorphine. These can be administered with a Luer-Jet or Luer Lock Prefilled Syringe of 2 mg/2 mL naloxone hydrochloride.
- the IMS Luer-JetTM system is a needleless prefilled emergency syringe.
- the CB1 inhibitor is administered with flumazenil or other benzodiazepine antagonist.
- the CB1 inhibitor is administered with both an opioid and a benzodiazepine antagonist in a single formulation.
- devices and methods described herein provide an overdose rescue pen that an emergency responder or others can use to treat an unresponsive person suspected of a drug overdose where the drug(s) in question are unknown.
- Said pen in some instances includes one or more of a narcotic antagonist, a benzodiazepine antagonist, and a cannabinoid antagonist such as ANEB-001, or a CB1 neutral antagonist.
- Formulations described herein are in some instances are configured for IV, IM, subcutaneous or other injection, or for intranasal delivery.
- Intranasal formulations comprising certain polymers in some instances increase the residence time of active compounds on the mucosal membranes.
- the pH of the formulation and/or the ionization state of the active compound(s) are in some instances taken into consideration for more effective transport across the nasal mucosa.
- a formulation described herein may comprise a CB1 inhibitor and one or more active agents.
- a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (w/w).
- a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (molar ratio).
- the CB1 inhibitor is administered with the one or more active agents as a single formulation.
- the CB1 inhibitor is administered with the one or more active agents as two or more formulations.
- a CB1 inhibitor may be administered in combination with one or more active agents.
- the active agent is an anxiolytic agent. In some instances, the active agent is a cannabinoid. In some instances, the cannabinoid is cannabidiol (CBD). In some instances, the active agent is CBG (Cannabigerol), CBD (Cannabidiol), CBC (Cannabichromene), CBGV (Cannabigerivarin), THCV (Tetrahydrocannabivarin), CBDV (Cannabidivarin), or CBCV (Cannabichromevarin).
- Formulations comprising a CB1 inhibitors may comprise one or more active agents (e.g., CBD).
- a formulation comprises about 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg, 60 mg, 75 mg, 100 mg, 125 mg, or 150 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, 150, 300, 500, or 800 mg of CBD.
- Formulations comprising a CB1 inhibitors (such as ANEB-001) may comprise one or more active agents (e.g., CBD).
- a formulation comprises about 10-150 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, or 150 mg of CBD.
- a formulation comprises about 50-150 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, 150, 300, 500, or 800 mg of CBD. In some instances, a formulation comprises about 60-120 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, or 150, 300, 500, or 800 mg CBD. In some instances, a formulation comprises about 10-150 mg of ANEB-001 and 5-800 mg of CBD. In some instances, a formulation comprises about 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg, 60 mg, 75 mg, 100 mg, 125 mg, or 150 mg of ANEB-001 and 5-800 mg of CBD.
- compositions and formulations described herein may be administered as single or multiple doses.
- a CB1 inhibitor e.g., ANEB-001
- the overdose can also be from consumption of cannabis , a synthetic cannabinoid, or any compound that is an agonist at the CB1 receptor.
- methods described herein include treatments to children who inadvertently consume cannabis or cannabinoid edibles.
- any suspected overdose patient that presents as mentally disoriented or psychotic or cannot articulate the nature of their condition or the substances that have been ingested or administered can be treated with a CB1 inhibitor.
- a THC or SC overdose is treated by administration of a CB1 inhibitor and one or more active agents (e.g., opioid antagonist, benzodiazepine antagonist, cannabinoid, or other active agent).
- active agents e.g., opioid antagonist, benzodiazepine antagonist, cannabinoid, or other active agent.
- the CB1 inhibitor and one or more active agents are administered as a single formulation.
- a CB1 antagonist e.g., ANEB-001
- IV intravenous
- IM intramuscular
- SC subcutaneous
- endotracheal sublingual
- buccal intralingual
- SC submental
- intranasal administration e.g., endotracheal
- a CB1 inhibitor is formulated in an injector pen for on-site administration to an overdose patient as well as the use of a CB1 inhibitor by emergency responders to treat THC or SC overdose outside of the hospital.
- the methods described herein also include the use of a CB1 inhibitor to treat cannabinoid hyperemesis syndrome and the use of various formulations and administration methods for that treatment, including the use of a CB1 inhibitor in suppository form to treat cannabinoid hyperemesis syndrome.
- a CB1 inhibitor is formulated for rapid nasal injection.
- CB1 antagonists prevent, treat or reduce the severity of various medical conditions and symptoms, including, but not limited to obesity, appetite disorder, another metabolic disorder, drug addiction and/or mental illness.
- CB1 antagonists are used for the treatment of: addiction, alcoholism, Alzheimer's disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelination related disorders, diabetes, diabetic neuropathy, diarrhea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple
- the methods described herein include pre-exposure prophylaxis treatments.
- CB1 antagonism which in some instances includes anhedonia, potentially makes them unsuitable for chronic use.
- a CB1 antagonist such as ANEB-001
- a CB1 inhibitor is used to prevent effects from second hand smoke from marijuana.
- the method of using a CB1 inhibitor includes use by someone who wishes to gain acceptance to a situation or group by smoking marijuana or SCs, but also wants to remain mentally alert, such as during an undercover police or law enforcement investigation.
- the method reduces the subject's ability to experience euphoria after inhaling or consuming Cannabis or a synthetic cannabinoid.
- the methods described herein include use of a CB1 inhibitor to treat cannabinoid hyperemesis syndrome.
- the use of the CB1 inhibitor in a suppository form is used to treat cannabinoid hyperemesis syndrome.
- Methods described herein may be used to treat a patient with a known or suspected acute drug overdose. In some instances, this is determined by the judgement of a qualified healthcare professional or emergency medical technician. In some instances, a lack of or reduced response to prior overdose treatments indicates a potential cannabinoid overdose. Such a patient is in some instances subsequently treated using the CB1 inhibitors described herein. In some instances, a patient is treated with a prior treatment comprising administration of an opiate antagonist, activated charcoal, or emetic. In some instances, the prior treatment is orogastric lavage or whole bowel irrigation.
- a CB1 inhibitor may be administered after confirmation of a cannabinoid overdose by one or more testing methods.
- the testing method is a blood test.
- the blood test comprises determination of the cannabinoid (or synthetic cannabinoid) plasma concentration.
- a patient is administered a CB1 inhibitor (e.g., ANEB-001) when his or her cannabinoid plasma concentration is at least 25, 50, 125, 150, 175, 200, 225, 250, 275, 300, 325, or at least 350 ug/L.
- a patient is administered a CB1 inhibitor (e.g., ANEB-001) when his or her cannabinoid plasma concentration is 25-300 ug/L, 50-300 ug/L, 75-300 ug/L, 100-300 ug/L, 125-300 ug/L, or 200-400 ug/L.
- a CB1 inhibitor e.g., ANEB-001
- a CB1 inhibitor (e.g., ANEB-001) may be administered to obtain diagnostic information about whether a patient is suffering from a cannabinoid or synthetic cannabinoid overdose. If a patient's mental state fails to improve upon administration of a CB1 inhibitor, other etiologies of confusion or altered mental state in some instances are considered, including intoxication with other substances, psychiatric illnesses, metabolic conditions and inflammatory, infectious or traumatic conditions of the brain. Treatment with a CB1 inhibitor in some instances is used for diagnostic purposes.
- a CB1 inhibitor may be administered in combination with one or more active agents.
- the active agent is an anxiolytic agent.
- the active agent is a cannabinoid.
- the cannabinoid is cannabidiol (CBD).
- CBD cannabidiol
- the active agent is CBG (Cannabigerol), CBD (Cannabidiol), CBC (Cannabichromene), CBGV (Cannabigerivarin), THCV (Tetrahydrocannabivarin), CBDV (Cannabidivarin), or CBCV (Cannabichromevarin).
- a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (w/w). In some instances, a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (molar ratio). In some instances, the CB1 inhibitor is administered with the one or more active agents as a single formulation. In some instances, the CB1 inhibitor is administered with the one or more active agents as two or more formulations.
- a patient may be monitored for improvement.
- Monitoring in some instances comprises heart rate monitoring, respiration monitoring, or measures such as patient cognitive function or behavior.
- monitoring comprises patient-reported feelings or answers to verbal or written interrogatories.
- CB1 inhibitors may be dosed in various amounts. In some instances, the CB1 inhibitor is dosed at about 1, 2, 5, 10, 25, 40, 50, 75, 90, 100, or about 150 mg. In some instances, the CB1 inhibitor is dosed at no more than 1, 2, 5, 10, 25, 40, 50, 75, 90, 100, or no more than 150 mg. In some instances, the CB1 inhibitor is dosed at least at 1, 2, 5, 10, 25, 40, 50, 75, 90, 100, or at least 150 mg. In some instances, the CB1 inhibitor is dosed at 1-200, 1-100, 1-50, 2-100, 5-100, 10-150, 10-200, 20-120, 50-125, 50-200, or 75-150 mg. In some instances, the CB1 inhibitor is dosed orally. In some instances, the CB1 inhibitor is dosed rectally.
- CB1 inhibitors may be administered in an oral dosage form.
- ANEB-001 is dosed (oral) at 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg or more, typically taken once, or once daily.
- ANEB-001 at 30 mg/kg to 10 mg/kg i.p. is in some instances administered subcutaneously.
- a single dose of ANEB-001 i.p. at 0.1 mg/kg is in some instances used.
- a CB1 inhibitor test employing forty-two male volunteers to receive one of three oral drug regimens, 40 mg daily for 15 days, placebo for 14 days, then 90 mg on day 15, or placebo for 15 days can be used test effectiveness.
- Oral dosages of ANEB-001 are in some instances selected from one or more of 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, or 40 mg once daily. In some instances, oral dosages of ANEB-001 are about 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg, 50 mg, 60 mg, 75 mg, 90 mg, or about 100 mg. While preferably delivered as an acute therapy, ANEB-001 is administered daily for up to 2, 4, 6, 10, 12, 15, 20, 25, or up to 28 days. In some instances, ANEB-001 is administered as a single acute dosage.
- CB1 inhibitors (such as ANEB-001) may be administered with one or more active agents, such as CBD. In some instances, a CB1 inhibitor is administered with 0.5, 1, 2, 5, 10, 20, 50, 75, 100, or 150 mg of CBD.
- the present disclosure provides a method of treating known or suspected acute drug overdose reaction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of CB1 inhibitor, or the pharmaceutical composition as described herein.
- the subject shows signs of an acute cannabinoid overdose.
- the acute cannabinoid overdose is caused by a compound from the Cannabis genus.
- the acute cannabinoid overdose is caused by a synthetic cannabinoid.
- the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids.
- the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids.
- the synthetic cannabinoid is capable of binding to the Cannabinoid (CB1) receptor.
- the subject shows signs of cannabinoid hyperemesis syndrome.
- the method further comprising treatment for drug overdose prior to treatment with the CB1 inhibitor.
- the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic.
- the present disclosure provides a method of using the CB1 inhibitor, or the pharmaceutical composition as described herein, comprising administering a therapeutically effective amount of the CB1 inhibitor prior to exposure to a cannabinoid.
- the cannabinoid is tetrahydrocannabinol (THC).
- the present disclosure provides a method of treating a subject suspected of a drug overdose, comprising administering a therapeutically effective amount of the CB1 inhibitor to the subject and monitoring said subject for reduced symptoms associated with overdose.
- the monitoring comprises monitoring heart rate or respiration.
- the method further comprising a diagnostic test prior to treatment with the CB1 inhibitor.
- the diagnostic test is a blood test.
- the subject has a cannabinoid plasma concentration of at least 25 ⁇ g/L.
- the diagnostic test is a blood test.
- the subject has a cannabinoid plasma concentration of at least 50 ⁇ g/L.
- the subject has a cannabinoid plasma concentration of about 25 ⁇ g/L to 350 ⁇ g/L.
- the subject has a cannabinoid plasma concentration of about 50 ⁇ g/L to 350 ⁇ g/L.
- the subject has a cannabinoid plasma concentration of about 75 ⁇ g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 100 ⁇ g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 150 ⁇ g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 200 ⁇ g/L to 350 ⁇ g/L.
- the amount of the CB1 inhibitor is between about 1 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 5 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 10 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 15 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 20 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 25 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 30 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 35 mg to about 200 mg.
- the amount of the CB1 inhibitor is between about 40 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 45 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 50 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 75 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 100 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 125 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 150 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 175 mg to about 200 mg.
- the amount of the CB1 inhibitor is between about 1 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 5 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 10 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 15 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 20 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 25 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 30 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 35 mg to about 300 mg.
- the amount of the CB1 inhibitor is between about 40 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 45 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 50 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 75 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 100 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 125 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 150 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 175 mg to about 300 mg.
- the amount of the CB1 inhibitor is 25-500, 25-400, 25-300, 25-250, 25-200, 25-150, 25-100, or 25-75 mg. In another embodiment, the amount of the CB1 inhibitor is 50-500, 50-400, 50-300, 50-250, 50-200, 50-150, 50-100, or 50-75 mg. In another embodiment, the amount of the CB1 inhibitor is 75-500, 75-400, 75-300, 75-250, 75-200, 75-150, 75-100, or 75-125 mg. In another embodiment, the amount of the CB1 inhibitor is 100-500, 100-400, 100-300, 100-250, 100-200, 100-150, 100-125 mg.
- the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 10 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 15 minutes. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 45 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 20 minutes.
- the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in 5-60, 5-45, 5-30, 5-25, 5-20, 5-15, 5-10, 10-60, 10-120, 10-30, 20-60, 20-120, 50-120, 60-120, or 90-120 minutes.
- the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 50 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 20 minutes after oral administration.
- the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 10 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 5 minutes after oral administration.
- the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 50 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 30 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 20 minutes after oral administration.
- the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 10 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 5 minutes after oral administration.
- CB1 inhibitor is dosed to provide a Tmax of no more than 5, 4, 3, 2.5, 2.25, 2, 1.75, 1.5, 1.25, 1, 0.75, 0.5, or 0.25 hours. In some instances, CB1 inhibitor is dosed to provide a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- CB1 inhibitor dosed at 100-200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- CB1 inhibitor dosed at 25-250 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- CB1 inhibitor dosed at no more than 200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- CB1 inhibitor dosed at no more than 150 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- CB1 inhibitor dosed at no more than 100 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- the present disclosure provides a method of treating known or suspected acute drug overdose reaction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide, or the pharmaceutical composition as described herein.
- the subject shows signs of an acute cannabinoid overdose.
- the acute cannabinoid overdose is caused by a compound from the Cannabis genus.
- the acute cannabinoid overdose is caused by a synthetic cannabinoid.
- the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids.
- the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids.
- the synthetic cannabinoid is capable of binding to the Cannabinoid (CB1) receptor.
- the subject shows signs of cannabinoid hyperemesis syndrome.
- the method further comprising treatment for drug overdose prior to treatment with the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide.
- the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic.
- the present disclosure provides a method of using the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide, or the pharmaceutical composition as described herein, comprising administering a therapeutically effective amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide prior to exposure to a cannabinoid.
- the cannabinoid is tetrahydrocannabinol (THC).
- the present disclosure provides a method of treating a subject suspected of a drug overdose, comprising administering a therapeutically effective amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide to the subject and monitoring said subject for reduced symptoms associated with overdose.
- the monitoring comprises monitoring heart rate or respiration.
- the method further comprising a diagnostic test prior to treatment with the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide.
- the diagnostic test is a blood test.
- the subject has a cannabinoid plasma concentration of at least 25 ⁇ g/L.
- the diagnostic test is a blood test.
- the subject has a cannabinoid plasma concentration of at least 50 ⁇ g/L.
- the subject has a cannabinoid plasma concentration of about 25 ⁇ g/L to 350 g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 50 g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 75 ⁇ g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 100 ⁇ g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 150 ⁇ g/L to 350 ⁇ g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 200 ⁇ g/L to 350 ⁇ g/L.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 1 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 5 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 10 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 15 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 20 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 25 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 30 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 35 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 40 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 45 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 50 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 75 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 100 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 125 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 150 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 175 mg to about 200 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 25-500, 25-400, 25-300, 25-250, 25-200, 25-150, 25-100, or 25-75 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 50-500, 50-400, 50-300, 50-250, 50-200, 50-150, 50-100, or 50-75 mg.
- the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 75-500, 75-400, 75-300, 75-250, 75-200, 75-150, 75-100, or 75-125 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 100-500, 100-400, 100-300, 100-250, 100-200, 100-150, 100-125 mg.
- the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 10 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 15 minutes. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 45 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 20 minutes.
- the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in 5-60, 5-45, 5-30, 5-25, 5-20, 5-15, 5-10, 10-60, 10-120, 10-30, 20-60, 20-120, 50-120, 60-120, or 90-120 minutes.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 50 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 20 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 10 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 5 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 50 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 30 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 20 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 10 minutes after oral administration.
- the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 5 minutes after oral administration.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is dosed to provide a Tmax of no more than 5, 4, 3, 2.5, 2.25, 2, 1.75, 1.5, 1.25, 1, 0.75, 0.5, or 0.25 hours.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is dosed to provide a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at 100-200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at 25-250 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at no more than 200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at no more than 150 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at no more than 100 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- the CB1 inhibitor (e.g., ANEB-001) has a half-life of at least 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or at least 24 hours. In some embodiments, the CB1 inhibitor has a half-life of 2-24, 2-12, 2-8, 4-24, 4-16, 4-12, 4-8, 6-12, 6-16, 6-10, 8-24, 8-16, 8-12, 12-24, or 12-48 hours.
- the CB1 inhibitor (e.g., ANEB-001) has a reduced seizure liability relative to other CB1 inhibitors.
- ANEB-001 has a reduced seizure liability relative to other CB1 inhibitors.
- ANEB-001 has a reduced seizure liability relative to other CB1 inhibitors.
- ANEB-001 has a reduced seizure liability relative to drinabant, taranabant, or rimonabant. In some instances, seizure liability is reduced by 10, 20, 50, 75, 100, 200, 400, 500, 1000, or 2000 percent.
- the CB1 inhibitor (e.g., ANEB-001) does not inhibit one or more P450 enzymes.
- the CB1 inhibitor is metabolized by one or more of CYP3A4, CYP2C9, CYP2C19, CYP1A2, CYP2E1, CYP2D6, and CYP2A6.
- the CB1 inhibitor does not inhibit CYP3A4.
- the CB1 inhibitor comprises an IC 50 of individual CYP450s of less than 100, 80, 70, 60, 50, 40, 30, 20, or 10 micromolar in human liver microsomes.
- the term “about” is intended to qualify the numerical values which it modifies, denoting such a value as variable within a range.
- the term “about” should be understood to mean the greater of the range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, considering significant figures, and the range which would encompass the recited value plus or minus 20%.
- agonist refers to a moiety that interacts with, and activates, a receptor and thereby initiates a physiological or pharmacological response characteristic of that receptor.
- the term “antagonist” refers to a compound that binds to a receptor, such as CB1, but which does not activate the intracellular response(s) initiated by an active agonist compound of the receptor.
- the antagonist can thereby inhibit the intracellular responses that would be elicited by an agonist or partial agonist if present.
- An antagonist does not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
- inverse agonist refers to a moiety that binds to the endogenous form of the receptor or to the constitutively activated form of the receptor and which inhibits the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of an agonist or partial agonist.
- a compound can behave like an antagonist while under other conditions it can behave as an inverse agonist. Functionally, both an antagonist and an inverse agonist can block and/or reverse the effects of an agonist or partial agonist.
- a CB1 inhibitor includes compounds which act as antagonists or inverse agonists.
- the term “neutral antagonist” is an antagonist that does not change the baseline response level of the receptor when it binds to receptor.
- a neutral antagonist comprises ANEB-001.
- symptom(s) of cannabinoid overdose is “apparent” or “suspected” when, in the judgment of a trained healthcare provider or emergency responder, the patient has one or more symptom(s) associated with a cannabinoid overdose.
- a cannabinoid overdose is suspected from an absence or reduced response to other overdose related medical treatments (e.g., opioid antagonists, antipsychotics, or other overdose treatment).
- reversal of symptom(s) of cannabinoid overdose is “apparent” when, in the judgment of a trained healthcare provider or emergency responder, the symptom(s) have been reduced or abated to a noticeable degree.
- a provider may use any appropriate measure to quantify the reversal of symptom(s), e.g., a visual analog scale for self-reporting, a heart rate monitor for tachycardia, an improved affect, etc.
- “Apparent” reversal of symptom(s) includes, but need not extend to, complete reversal.
- cannabinoid is synonymous with “cannabinoid receptor agonist” and refers to a compound which binds to and activates a cannabinoid receptor.
- the term includes both natural and synthetic compounds.
- SC synthetic cannabinoid
- Most SCs are lipid-soluble, non-polar, small molecules that are fairly volatile, and often have a side-chain of 5-9 saturated carbon atoms. SCs are associated with psychotropic activity from binding CB1 receptors.
- Classical cannabinoids are analogs of THC that are based on a dibenzopyran ring; examples include nabilone, dronabinol, and the ( ⁇ )-1,1-dimethylheptyl analog of 11-hydroxy-A8-tetrahydrocannabinol.
- Non-classical cannabinoids include cyclohexylphenols such as cannabicyclohexanol.
- Hybrid cannabinoids have a combination of classical and non-classical cannabinoid structural features.
- Aminoalkylindoles are structurally dissimilar to THC and include naphthoylindoles such as 1-pentyl-3-(1-naphthoyl)indole, phenylacetylindoles such as 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250), and benzoylindoles such as 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; they are the most common SCs found in SC blends due to relative ease of synthesis.
- naphthoylindoles such as 1-pentyl-3-(1-naphthoyl)indole
- phenylacetylindoles such as 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)
- benzoylindoles such as 1-[(N-methylpiperidin-2-y
- Eicosanoid SCs are analogs of endocannabinoids such as anandamide.
- SCs are CB1 activators, such as agonists.
- cannabinoid receptor antagonist or “CB1 antagonist” refers to a compound that binds to and blocks or dampens the normal biological function of the CB1 receptor and its signaling. This activity can occur in the presence of a natural or synthetic agonist or partial agonist.
- the term includes cannabinoid receptor antagonists that are selective or nonselective for the CB1 receptor subtype.
- active agent is used to indicate a chemical entity which has biological activity.
- an “active agent” is a compound having pharmaceutical utility.
- an active agent may be an anti-cancer therapeutic.
- modulation refers to a change in activity as a direct or indirect response to the presence of a chemical entity as described herein, relative to the activity of in the absence of the chemical entity.
- the change may be an increase in activity or a decrease in activity, and may be due to the direct interaction of the compound with the target or due to the interaction of the compound with one or more other factors that in turn affect the target's activity.
- the presence of the chemical entity may, for example, increase or decrease the target activity by directly binding to the target, by causing (directly or indirectly) another factor to increase or decrease the target activity, or by (directly or indirectly) increasing or decreasing the amount of target present in the cell or organism.
- terapéuticaally effective amount of a chemical entity described herein refers to an amount effective, when administered to a human or non-human subject, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prevention of disease.
- Treating” or “treatment” encompasses administration of Compound 1, or a pharmaceutically acceptable salt thereof, to a mammalian subject, particularly a human subject, in need of such an administration and includes (i) arresting the development of clinical symptoms of the disease, such as cancer, (ii) bringing about a regression in the clinical symptoms of the disease, such as cancer, and/or (iii) prophylactic treatment for preventing the onset of the disease, such as cancer.
- a “pharmaceutically acceptable” component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochlorate, carbonate, phosphate, hydrogenphosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, malonate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, gluconate, methanesulfonate, Tris (hydroxymethyl-aminomethane), p-toluenesulfonate, propionate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, oxalate, pamoate, and alkanoate such as acetate, HOOC—(CH 2 ) n —COOH where n is 0-4, and like salts.
- inorganic acids such as hydrochlorate, carbonate, phosphate, hydrogen
- salts include sulfate, methanesulfonate, bromide, trifluoroacetate, picrate, sorbate, benzilate, salicylate, nitrate, phthalate or morpholine.
- Pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium.
- the free base can be obtained by basifying a solution of the acid salt.
- an addition salt particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
- Those skilled in the art will recognize various synthetic methodologies that may be used to prepare non-toxic pharmaceutically acceptable addition salts.
- subject refers to a mammal that has been or will be the object of treatment, observation or experiment.
- the methods described herein can be useful in both human therapy and veterinary applications.
- the subject is a human.
- Prodrugs described herein include any compound that becomes Compound 1 when administered to a subject, e.g., upon metabolic processing of the prodrug.
- pharmaceutically acceptable salts includes “prodrugs” of pharmaceutically acceptable salts.
- Examples of prodrugs include derivatives of functional groups, such as a carboxylic acid group, in Compound 1.
- Exemplary prodrugs of a carboxylic acid group include, but are not limited to, carboxylic acid esters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters, and aryloxyalkyl esters.
- exemplary prodrugs include lower alkyl esters such as ethyl ester, acyloxyalkyl esters such as pivaloyloxymethyl (POM), glycosides, and ascorbic acid derivatives.
- exemplary prodrugs include amides of carboxylic acids.
- a “solvate” is formed by the interaction of a solvent and a compound.
- the term “compound” is intended to include solvates of compounds.
- “pharmaceutically acceptable salts” includes solvates of pharmaceutically acceptable salts. Suitable solvates are pharmaceutically acceptable solvates, such as hydrates, including monohydrates and hemi-hydrates. Also included are solvates formed with the one or more crystallization solvents.
- compositions recited herein include pharmaceutically acceptable salts, chelates, non-covalent complexes, prodrugs, and mixtures thereof.
- a “chelate” is formed by the coordination of a compound to a metal ion at two (or more) points.
- the term “compound” is intended to include chelates of compounds.
- pharmaceutically acceptable salts includes chelates of pharmaceutically acceptable salts.
- non-covalent complex is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule.
- complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
- Such non-covalent complexes are included in the term “compound”.
- pharmaceutically acceptable salts include “non-covalent complexes” of pharmaceutically acceptable salts.
- significant refers to any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p ⁇ 0.05.
- mice Six C57 mice (Charles River, Wilmington, MA) were administered A9-tetrahydrocannabinol (THC) 3 mg/kg ip, 10 min pre-test. The mice exhibited reduced locomotor activity when placed in automated locomotor activity cages for 15 min. In this apparatus, four qualitatively different measures of locomotor activity are automatically scored.
- ANEB-001 compound 1 given orally at a dose of 30 mg/kg and 30 min pre-test, significantly reversed the action of THC on the total active time parameter of these locomotor measures ( FIG. 1 ). The magnitude of the effect is similar to that elicited by rimonabant given at 3 mg/kg po, and given 30 min pre-test.
- ANEB-001 Human subjects were assigned to six different dosage groups of ANEB-001. Groups assigned to receive dosages of 1 mg, 5 mg, 25 mg, 100 mg, or 200 mg had six subjects each, and the 150 mg dosage group had four subjects. ANEB-001 was administered orally to subjects in each group, and the plasma concentration of ANEB-001 in each subject was measured as a function of time after dosing ( FIG. 2 ). ANEB-001 had a T max of approximately 1-1.6 hours, and a terminal elimination half-life up to 19 days.
- a patient admitted to the emergency room is diagnosed with acute THC poisoning from overconsumption of cannabinoid products, such as edibles.
- the patient is administered a 75 mg oral dose of a CB1 inhibitor, such as ANEB-001, and monitored for signs of improvement (heart rate, cognitive response, etc.).
- a CB1 inhibitor such as ANEB-001
- a human subject diagnosed or suspected of acute THC poisoning from overconsumption of cannabinoid products is treated by a clinician or first responder with a fast-acting nasal formulation comprising a CB1 inhibitor (e.g., ANEB-001) via nasal injector.
- the fast-acting nasal formulation is designed to provide effective amounts of the CB1 inhibitor in no more than 10 minutes.
- a patient admitted to the emergency room is diagnosed with acute THC poisoning from overconsumption of cannabinoid products, such as edibles.
- the patient is administered a formulation comprising a 75 mg oral dose of a CB1 inhibitor such as ANEB-001 and CBD (150 mg) and monitored for signs of improvement (heart rate, cognitive response, etc.).
- a CB1 inhibitor such as ANEB-001 and CBD (150 mg)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose or suspected of a drug overdose. Further described herein are uses wherein the CB1 inhibitor is ANEB-001. Further described herein are treatments with a CB1 inhibitor for THC or synthetic cannabinoid overdose.
Description
- This application claims the benefit of U.S. provisional patent application No. 63/115,487 filed on Nov. 18, 2020, which is incorporated herein by reference in its entirety.
- The widespread use of A9-tetrahydrocannabinol (THC) and synthetic cannabinoids (SCs) has resulted in an increased number of emergency room visits secondary to symptoms of cannabinoid overdose; this is especially notable after cannabis is legalized in a jurisdiction. A medical need therefore exists to treat THC and SC related-overdoses.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 illustrates a plot of the effect of ANEB-001 on THC-induced hypolocomotion in mice. The total active time is plotted against conditions of vehicle only, treatment with THC, and treatment with ANEB-001 and THC. veh: vehicle; THC: tetrahydrocannabinol. -
FIG. 2 illustrates a plot of a single ascending oral dose study in humans of ANEB-001. Plasma concentrations (ng/mL) of ANEB-001 are plotted against time. - Described herein are compositions, formulations, methods, and devices for treating THC and SC overdose. In some embodiments, the overdose is an acute overdose. In some embodiments, methods described herein comprise use of a CB1 inhibitor. Accordingly, described herein are compositions, formulations, and methods for reversing the symptoms of cannabinoid overdose using the CB1 antagonist ANEB-001, or a salt, adjunct, or polymorph thereof. Other aspects of the compositions and methods described herein are described below or throughout this specification.
- Provided herein are methods of using a pharmaceutical composition comprising a CB1 inhibitor, the method comprising administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has a known or suspected acute drug overdose reaction. Provided herein are methods of using a pharmaceutical composition comprising a CB1 inhibitor, the method comprising administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has a known or suspected acute drug overdose reaction, wherein the CB1 inhibitor has the structure of formula (I):
- or a pharmaceutically acceptable salt or prodrug thereof,
-
- wherein
- R1 is aryl or heteroaryl;
- R2 is alkyl, aryl or heteroaryl;
- R3 is alkyl, aryl, heteroaryl, NR9R10, OR11, or NR16C(O)R17;
- Y is C═O, C═S, SO2, or (CR7R8)p;
- R7 and R8 are independently selected from H and lower alkyl;
- R9 is selected from H, alkyl, aryl, heteroaryl, and non-aromatic heterocyclic groups, or together with R10 forms a saturated 4, 5, 6, or 7 membered ring optionally containing an additional heteroatom selected from N and O;
- R10 is selected from H and lower alkyl, or together with R9 forms a saturated 4, 5, 6, or 7 membered ring optionally containing an additional heteroatom selected from N and O;
- R11 and R12 are independently selected from H and lower alkyl;
- R15 is selected from alkyl and aryl;
- R16 is selected from H and lower alkyl;
- R17 is selected from alkyl, aryl, and heteroaryl;
- m is 1 or 2;
- n is 1 or 2; and
- p is 1, 2, 3 or 4. Further provided herein are methods wherein m is 1 and n is 1. Further provided herein are methods wherein R1 and R2 are independently aryl. Further provided herein are methods wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [—CH—O—] group. Further provided herein are methods wherein R11 and R12 are hydrogen. Further provided herein are methods wherein R3 is NR9R10, and R9 and R10 are independently lower alkyl or hydrogen.
- Further provided herein are methods wherein the CB1 inhibitor comprises the structure of formula (Ia):
- or a pharmaceutically acceptable salt or prodrug thereof.
- Further provided herein are methods wherein R1 and R2 are independently selected from a group of formula (II):
-
- wherein
- R4, R5, and R6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, NR14C(O)R19, NR14SO2R20, COOR19, OC(O)R20, CONR13R14 and SO2NR13R14, R13 and R14 are independently selected from hydrogen and alkyl or form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O, and S; R19 is selected from H, alkyl, aryl and heteroaryl, and R20 is selected from alkyl, aryl and heteroaryl. Further provided herein are methods wherein at least one of R4, R5, and R6 are chloro or trifluoromethyl. Further provided herein are methods wherein the patient shows signs of an acute cannabinoid overdose. Further provided herein are methods wherein the patient shows signs of cannabinoid hyperemesis syndrome. Further provided herein are methods wherein the method comprises treatment for drug overdose prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic. Further provided herein are methods wherein the prior treatment comprises one or more of orogastric lavage or whole bowel irrigation. Further provided herein are methods wherein the method further comprises a diagnostic test prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the diagnostic test is a blood test. Further provided herein are methods wherein the patient has a cannabinoid plasma concentration of at least 50 μg/L. Further provided herein are methods wherein the patient has a cannabinoid plasma concentration of at least 100 μg/L. Further provided herein are methods wherein the patient has a cannabinoid plasma concentration of 50 μg/L to 300 μg/L. Further provided herein are methods wherein the pharmaceutical composition is prepared as an oral, sublingual, buccal, rectal, nasal, or parenteral dose. Further provided herein are methods wherein the CB1 inhibitor is cannabigerol, ibipinabant, otenabant, tetrahydrocannabivarin, virodhamine, rimonabant, or taranabant. Further provided herein are methods wherein the CB1 inhibitor has the structure:
- Further provided herein are methods wherein the dose of the CB1 inhibitor is 1 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 25 mg to 200 mg. Further provided herein are methods wherein the CB1 inhibitor is formulated as an oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, suppository, or intranasal administration. Further provided herein are methods wherein further comprising administering a pharmaceutically acceptable alkaline agent. Further provided herein are methods wherein the pharmaceutical composition is formulated to deliver an effective dose of the CB1 inhibitor in no more than 10 min. Further provided herein are methods wherein the dose of the CB1 inhibitor or pharmaceutical composition thereof is 50 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor or pharmaceutical composition thereof delivers a therapeutically effective amount of the CB1 inhibitor in no more than 10 minutes. Further provided herein are methods wherein the dose of the CB1 inhibitor or pharmaceutical composition thereof delivers a therapeutically effective amount of the CB1 inhibitor in no more than 5 minutes. Further provided herein are methods wherein the amount of the CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. Further provided herein are methods wherein the amount of the CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration. Further provided herein are methods wherein the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 min. Further provided herein are methods wherein the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour.
Provided herein are methods of using a CB1 inhibitor as a pre-exposure prophylactic therapy comprising administering an effective amount of the CB1 inhibitor prior to exposure to a cannabinoid. Further provided herein are methods wherein the cannabinoid is tetrahydrocannabinol. Further provided herein are methods wherein CB1 inhibitor is formulated for oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, suppository, or intranasal administration. Further provided herein are methods wherein the CB1 inhibitor has the structure: - Further provided herein are methods wherein the dose of the CB1 inhibitor is 1 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 25 mg to 200 mg.
- Provided herein are methods of treating a patient suspected of a drug overdose comprising administering an effective amount of a CB1 inhibitor to a patient and monitoring the patient for reduced symptoms associated with overdose. Further provided herein are methods wherein monitoring comprises monitoring heart rate or respiration. Further provided herein are methods wherein the CB1 inhibitor has the structure:
- Further provided herein are methods wherein the dose of the CB1 inhibitor is 1 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 25 mg to 200 mg.
- Provided herein are injectable compositions for treating a suspected drug overdose, the composition comprising a CB1 inhibitor, an opioid antagonist, and a benzodiazepine antagonist. Further provided herein are methods wherein the benzodiazepine antagonist is flumazenil. Further provided herein are methods wherein the opioid antagonist is naloxone. Further provided herein are methods wherein the injectable composition is formulated in a single dose injectable device. Further provided herein are methods wherein the CB1 inhibitor has the structure
- Further provided herein are methods wherein the dose of the CB1 inhibitor is 1 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 25 mg to 200 mg.
- Provided herein are compositions for treating a suspected drug overdose, the composition comprising a CB1 inhibitor and an anxiolytic agent. Further provided herein are methods wherein the anxiolytic agent is a cannabinoid. Further provided herein are methods wherein the cannabinoid is cannabidiol. Further provided herein are methods wherein composition is formulated for intranasal delivery. Further provided herein are methods wherein the CB1 inhibitor has the structure
- Further provided herein are methods wherein the dose of the CB1 inhibitor is 1 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 25 mg to 200 mg.
- Provided herein are methods of using a pharmaceutical composition comprising a CB1 inhibitor, the method comprising orally administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has an acute drug overdose reaction, wherein the CB1 inhibitor has the structure:
- or a pharmaceutically acceptable salt thereof, wherein the dose of the CB1 inhibitor is 50 mg to 300 mg, and wherein the amount of CB1 inhibitor in the bloodstream of the patient reaches at least 200 ng/mL within one hour after oral administration. Further provided herein are methods wherein the patient shows signs of an acute cannabinoid overdose. Further provided herein are methods wherein the acute cannabinoid overdose is caused by a compound from the Cannabis genus. Further provided herein are methods wherein the acute cannabinoid overdose is caused by a synthetic cannabinoid. Further provided herein are methods wherein the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids. Further provided herein are methods wherein the patient shows signs of cannabinoid hyperemesis syndrome. Further provided herein are methods wherein the method further comprises treatment for drug overdose prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic. Further provided herein are methods wherein the method further comprises a diagnostic test prior to treatment with the CB1 inhibitor. Further provided herein are methods wherein the diagnostic test is a blood test. Further provided herein are methods wherein the patient has a cannabinoid plasma concentration of at least 50 μg/L. Further provided herein are methods wherein the patient has a cannabinoid plasma concentration of 50 μg/L to 300 μg/L. Further provided herein are methods wherein the dose of the CB1 inhibitor is 50 mg to 200 mg. Further provided herein are methods wherein the dose of the CB1 inhibitor is 75 mg to 200 mg. Further provided herein are methods wherein the CB1 inhibitor has the structure:
- Further provided herein are methods wherein the amount of CB1 inhibitor in the bloodstream of the patient reaches at least 200 ng/mL within 30 minutes after oral administration.
- Described herein are compositions, formulations, and methods for reversing cannabinoid overdose and/or one or more symptoms thereof comprising administering a CB1 inhibitor in an amount sufficient to reduce the severity of one or more overdose symptoms or reverse the cannabinoid overdose in a patient. Further described herein are fast-acting formulations comprising CB1 inhibitors for emergency/rescue applications. Further described herein are formulations comprising combinations of CB1 inhibitors and other active agents.
- Compositions, formulations, and methods described herein may comprise use of a CB1 inhibitor. In some embodiments, the CB1 inhibitor is a CB1 antagonist. In some embodiments, the CB1 inhibitor is a CB1 inverse agonist. In some embodiments, the CB1 inhibitor is a CB1 neutral antagonist. Certain embodiments include the use of the CB1 antagonist and a specific cannabinoid antagonist.
- Provided herein compounds having the structure of formula (I):
-
- wherein
- R1 is aryl or heteroaryl;
- R2 is alkyl, aryl or heteroaryl;
- R3 is alkyl, aryl, heteroaryl, NR9R10, OR11, or NR16C(O)R17;
- Y is C═O, C═S, SO2, or (CR7R8)p;
- R7 and R8 are independently selected from H and lower alkyl;
- R9 is selected from H, alkyl, aryl, heteroaryl, and non-aromatic heterocyclic groups, or together with R10 forms a saturated 4, 5, 6, or 7 membered ring optionally containing an additional heteroatom selected from N and O;
- R10 is selected from H and lower alkyl, or together with R9 forms a saturated 4, 5, 6, or 7 membered ring optionally containing an additional heteroatom selected from N and O;
- R11 and R12 are independently selected from H and lower alkyl;
- R15 is selected from alkyl and aryl;
- R16 is selected from H and lower alkyl;
- R17 is selected from alkyl, aryl and heteroaryl;
- m is 1 or 2;
- n is 1 or 2; and
- p is 1, 2, 3 or 4.
- In some embodiments, R1 and/or R2 is substituted with 1 to 3 substituents. In some embodiments, R1 and/or R2 is substituted with 1 or 2 substituents. In one embodiment, R1 and R2 are independently selected from a group —A(R4)(R5)(R6), where A is an aryl or heteroaryl ring, and where A may be selected from phenyl, naphthyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, pyridyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl and isobenzofuryl. In some embodiments, one of Rand R2 is aryl and the other is heteroaryl, or both R1 and R2 are aryl. In some embodiments, both R1 and R2 are monocyclic. In this embodiment, R4, R5, and R6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, NR14C(O)R19, NR14SO2R20, COOR19, OC(O)R20, CONR13R14 and SO2NR13R14, wherein R13 and R14 are independently selected from hydrogen and alkyl or may form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O and S; and R19 is selected from H, alkyl, aryl and heteroaryl and R20 is selected from alkyl, aryl and heteroaryl. The groups R1 and R2 may be the same or different, and in one embodiment are different. In some embodiments, R3 is NR9R10. In some embodiments, R3 is NR9R10, and R9 and R10 are independently lower alkyl or hydrogen. In some embodiments, Y is C═0. In some embodiments, Y is C═0 and R3 is NR9R10. In some embodiments, R3 is NR9R10, R9 is lower alkyl, and R10 is hydrogen.
- In some embodiments of a compound of Formula (I) where R4, R5, and R6 are selected from halo. In some embodiments, the halo group is fluoro, chloro, bromo or iodo. In some embodiments, the halo group is chloro or bromo. In some embodiments, R4, R5, and R6 are selected from alkyl, thioalkyl, alkoxy and alkylsulfonyl. In some embodiments, R4, R5, and R6 are selected from lower alkyl. In some embodiments, R4, R5, and R6 are selected from methyl and ethyl. Where R4, R5, and R6 are selected from haloalkyl, the alkyl is in some embodiments methyl, and the R4, R5, or R6 group is trifluoromethyl. Where R4, R5, and R6 are selected from haloalkoxy, the alkyl is in some embodiments methyl and the R4, R5, or R6 group is trifluoromethoxy or difluoromethoxy. In some embodiments, one or two of R4, R5, and R6 are hydrogen. In some embodiments, at least one of the R1 and R2 groups has a non-hydrogen substituent in the ortho-position(s) relative to the point of attachment to the [—CH—O—] group. The R1 or R2 groups may independently have one or two non-hydrogen substituents in said ortho position(s). Preferred ortho-substituents include halo and haloalkyl, as described herein. In some embodiments, ortho-substituents are chloro and trifluoromethyl. In some embodiments, if —Y—R3 is —C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroaryl; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl. In some embodiments, if Y R3 is C(O)NH(alkyl) then: R1 and/or R2 is selected from aryl, and m and n are 1.
- In some embodiments of a compound of Formula (I) where R13 and R14 form a 5- or 6-membered ring, the ring is 6-membered. In some embodiments, the ring is saturated or partially saturated. In some embodiments where the ring contains additional heteroatoms, such as N and O. In some embodiments, there are 0 or 1 additional heteroatoms.
- In some embodiments of a compound of Formula (I), R1 is selected from aryl. In some embodiments, R2 is selected from aryl or heteroaryl. In some embodiments, R3 is selected from NR9R10. In an alternative embodiment R3 is selected from alkyl, aryl and heteroaryl. In some embodiments, Y is selected from C═0, C═S and SO2. Where Y is selected from (CR7R)p, then R7 and/or R8 in some embodiments are hydrogen or methyl, and p is 1 or 2. Where Y is SO2, R3 is in some embodiments selected from alkyl, aryl and heteroaryl. Where Y is (CR7R8, in some embodiments p is 1, and R3 is selected from alkyl, aryl, heteroaryl. In some embodiments, R9 is selected from piperidinyl (such as 1-piperidinyl) and morpholinyl (such as 4-morpholinyl). In some embodiments, R9 is cyclic, such as aryl or heteroaryl, and the R9 group may be substituted with one or more substituent groups. In some embodiments, R9 is substituted with halo, nitro, or alkoxy haloalkyl.
- In some embodiments of a compound of Formula (I), the ring formed by NR9R10 may be substituted, and substituents include hydroxy, methoxy, mono- and di-alkyl amino and alkoxycarbonyl. In one embodiment (hereinafter referred to as embodiment (i)), R9 is selected from aryl, heteroaryl and a non-aromatic heterocyclic group, and R10 is selected from H and lower alkyl. In an alternative embodiment (hereinafter referred to as embodiment (ii)), R9 is selected from alkyl and R10 is selected from lower alkyl. In a further alternative embodiment hereinafter referred to as embodiment (iii)), R9 and R10 form a 4, 5, 6, or 7-membered ring, or a 5, 6, or 7-membered ring, optionally containing an additional heteroatom selected from N and 0.
- In some embodiments of a compound of Formula (I), m is 1 and/or n is 1. In some embodiments, both m and n are 1. Where m is 2, the R11 groups may be the same or different, but at least one of the R11 groups in the (CHR11)2 moiety is hydrogen. Where n is 2, the R2 groups may be the same or different, but at least one and optionally both of the R12 groups in the (CHR12)2 moiety is/are hydrogen. In some embodiments, R11 and R12 are independently selected from hydrogen and methyl. In some embodiments, at least one of R11 and R12 is hydrogen. In some embodiments, R15 is selected from alkyl, such as lower alkyl (substituted or unsubstituted). In some embodiments, R15 is selected from aryl, such as phenyl (substituted or unsubstituted). In one embodiment, R15 is selected from lower alkyl, benzyl and phenyl. In some embodiments, R16 is hydrogen. In some embodiments, R17 is lower alkyl, aryl, or heteroaryl, and in one embodiment is aryl.
- Provided herein are compounds having the structure of formula (Ia)
- or a pharmaceutically acceptable salt or prodrug thereof,
wherein -
- R1 and R2 are independently selected from aryl or heteroaryl; and
- R9 is hydrogen or alkyl;
- wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [—CH—O—] group.
- Provided herein are compounds having the structure of formula (Ia)
- or a pharmaceutically acceptable salt or prodrug thereof,
-
- wherein
- R1 and R2 are independently selected from aryl; and
- R9 is hydrogen or alkyl;
- wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [—CH—O—] group.
- In the compounds of formula (I) or (Ia), R1 and R2 are independently selected from substituted or unsubstituted phenyl or naphthyl. In some embodiments, R1 and R2 are independently selected from phenyl or naphthyl having 1 to 3 substituents. In one embodiment the substituent groups are selected from halogen and haloalkyl. In some embodiments, R1 and R2 are selected from mono-cyclic aromatic groups.
- In some embodiments of the compounds of formula (I) or (Ia), R1 and R2 are independently selected from a group of formula (II):
-
- wherein
- R4, R5, and R6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, NR14C(O)R19, NR14SO2R20, COOR19, OC(O)R20, CONR13R14 and SO2NR13R14, R13 and R14 are independently selected from hydrogen and alkyl or form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O, and S;
- R19 is selected from H, alkyl, aryl and heteroaryl, and
- R20 is selected from alkyl, aryl and heteroaryl.
- In some embodiments of the compounds of formula (I) or (Ia), the groups R1 and R2 in are the same or different, and in one embodiment are different. Where R4, R5, and R6 are selected from halo, the halo group is in some embodiments fluoro, chloro, bromo or iodo. Where R4, R5 and R6 are selected from alkyl, thioalkyl, alkoxy and alkylsulfonyl, the alkyl is in some embodiments lower alkyl. Where R4, R5, and R6 are selected from aminoalkyl, alkylaminoalkyl and dialkylaminoalkyl, the alkyl is selected from methyl and ethyl. Where R4, R5, and R6 are selected from dialkylaminoalkyl, the dialkylamino fragment is in some embodiments selected from cyclicamino, such as morpholino and piperazino. Where R4, R5, and R6 are selected from haloalkyl, the alkyl is in some embodiments methyl, and the R4, R5, or R6 group is trifluoromethyl. Where R4, R5, and R6 are selected from haloalkoxy, the alkyl is in some embodiments methyl and the R4, R5, or R6 group is selected from trifluoromethoxy or difluoromethoxy. In some embodiments, one or two of R4, R5, and R6 are hydrogen. At least one of the R1 and R2 groups has a non-hydrogen substituent in the ortho-position(s). The R1 or R2 groups in some embodiments independently have one or two non-hydrogen substituents in the ortho position(s) relative to the point of attachment to the [—CH—O—] group. Preferred ortho-substituents include halo and haloalkyl, as described herein. In some embodiments, ortho-substituents are chloro and trifluoromethyl. Where R13 and R14 form a 5- or 6-membered ring, the ring in some embodiments is 6-membered. Where the ring contains additional heteroatoms, in some embodiments, these are N and/or O. In some embodiments, there are 0 or 1 additional heteroatoms. In some embodiments, R13 and R14 are independently hydrogen or alkyl.
- In some embodiments of the compounds of formula (I) or (Ia), R9 is selected from hydrogen or alkyl. In some embodiments, R9 is alkyl. In some embodiments, R9 is selected from methyl, ethyl, propyl, sec-butyl, or tert-butyl. The alkyl group in some embodiments are substituted or unsubstituted, and in one embodiment is substituted. In some embodiments, one or two substituent groups are present. In some embodiments, substituents are hydroxy, alkoxy, thioalkyl, amino, mono- and dialkyl amino, alkoxycarbonyl, aryl, and heterocyclic groups including both heteroaryl and non-aromatic heterocyclic groups. Where R9 is an acyclic alkyl group, in some embodiments it is substituted by a cyclic alkyl group; and where R9 is a cyclic alkyl group in some embodiments it is substituted by an acyclic alkyl group. Where the substituent group is heteroaryl, in some embodiments the heteroaryl is a 5- or 6-membered ring containing one or more N, O, or S atoms, such as thiophenyl, furanyl, isoxazolyl, thiazolyl and benzothiophenyl. Other substituent groups in some embodiments include dihydrobenzofuranyl, dihydrobenzodioxinyl, tetrahydrofuranyl, pyrrolidinyl, oxopyrrolindyl and benzodioxolyl.
- In one embodiment of a compound of formula (I), R3 has the structure:
-
—(CHR9)n(CH2)mCR10R11R12 -
- wherein
- n is 0 or 1;
- m is 0, 1, 2 or 3;
- R9, R10, R11, and R12 are selected from hydrogen, alkyl, hydroxy, alkoxy, thioalkyl, amino, mono- and di-alkyl amino, alkoxycarbonyl and R13;
- wherein R13 is selected from aryl, heteroaryl and non-aromatic heterocyclic optionally substituted by one or more groups selected from alkyl, halogen, alkoxy, oxo, aryl, heteroaryl and non-aromatic heterocycle.
- In some embodiments of Formula (I) or (Ia), m is 0 or 1 or 2. In some embodiments, m is 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1 and m is 1. In one embodiment, at least one or two of R10, R11, and R12 are selected from hydrogen. In a further embodiment, at least two of R10, R11, and R12 are selected from methyl. In a further embodiment, R9 is selected from cyclic alkyl, including cyclopentyl, cyclohexyl, norbornanyl and adamantyl. In some embodiments, R9 groups are tertiary butyl, sec-butyl, isobutyl, isopropyl, n-propyl and ethyl.
- In some embodiments, the CB1 antagonist of Formula (I) or (Ia) is ((R)-(+)-N-tert-butyl-3-[(4-chloro)phenyl-(2-trifluoromethyl)phenyl]methoxyazetidine-1-carboxamide (Compound ANEB-001). In some embodiments, the CB1 antagonist is ((S)-(−)-N-tert-butyl-3-[(4-chloro)phenyl-(2-trifluoromethyl)phenyl]methoxyazetidine-1-carboxamide. In some embodiments, the CB1 antagonist is (N-tert-butyl-3-[(4-chloro)phenyl-(2-trifluoromethyl)phenyl]methoxyazetidine-1-carboxamide. In some embodiments, the CB1 antagonist is Cannabigerol. In some embodiments, the CB1 antagonist is ibipinabant. In some embodiments, the CB1 antagonist is otenabant. In some embodiments, the CB1 antagonist is tetrahydrocannabivarin. In some embodiments, the CB1 antagonist is virodhamine. In some embodiments, the CB1 inverse agonist is rimonabant. In some embodiments, the CB1 inverse agonist is taranabant. In some embodiments, the CB1 inverse agonist is surinabant or drinabant. In some embodiments, a composition or formulation described herein comprises two or more CB1 inhibitors. In some embodiments, the CB1 inhibitor is a neutral antagonist. In some instances, the CB1 inhibitors comprise one or more substitutions at the phenyl groups that function as effective neutral antagonists of CB1.
- In some instances, a CB1 inhibitor comprises a structure of formula (Ia), wherein R1 and R2 are substituted aromatic groups, and R3 is an optionally substituted C1-C6 alkyl group. In some instances, R3 is tert-butyl. In some instances, R3 is isopropyl. In some instances, R3 is sec-butyl. In some instances, R1 is a substituted aromatic group. In some instances, R1 is an optionally substituted phenyl group. In some instances, R1 is a phenyl group substituted with a halogen (e.g., F, Cl, Br, I). In some instances, R1 is a phenyl group substituted with Cl. In some instances, R1 is a phenyl group para substituted in (4-position) with a halogen (e.g., F, Cl, Br, I). In some instances, R1 is a 4-chlorophenyl group. In some instances, R2 is a substituted aromatic group. In some instances, R2 is an optionally substituted phenyl group. In some instances, R2 is a phenyl group substituted with a C1-C5 alkyl group. In some instances, R2 is a phenyl group substituted with a C1-C5 trifluoroalkyl group. In some instances, R2 is a phenyl group substituted with a trifluoromethyl group. In some instances, R2 is a phenyl group ortho substituted in (4-position) with a C1-C5 trifluoroalkyl group. In some instances, R2 is a 2-trifluoromethylphenyl group. In some embodiments, the CB1 inhibitor is compound ANEB-001, having the following structure:
- Methods of producing ANEB-001 and related compounds (and enantiomers thereof) are known in the art (see Example 81 of U.S. Pat. No. 7,504,522 which is incorporated by reference). In some embodiments, the CB1 inhibitor has the structure:
- In some embodiments, the CB1 inhibitor has the structure:
- In some embodiments, a CB1 inhibitor is a compound of Table 1.
-
TABLE 1 # Name Structure 1 3-[(R)-2-(trifluoromethyl)-4′-chlorobenzhydryloxy]- N-(tert-butyl)azetidine-1-carboxamide (ANEB-001) 2 3-(2,4,4′-trichlorobenzhydryloxy)-N-(tert- butyl)azetidine-1-carboxamide 3 3-(2,4′-dichlorobenzhydryloxy)-N-(ethyl propionate- 2-yl)azetidine-1-carboxamide 4 3-(2,4′-dichlorobenzhydryloxy)-N-(tert- butyl)azetidine-1-carboxamide 5 3-(2,4′-dichlorobenzhydryloxy)-N-(2-thiophen-2-yl ethyl)azetidine-1-carboxamide 6 3-(2,4′-dichlorobenzhydryloxy)-N-[ethyl 4- (methylthio)butyrate-2-yl]azetidine-1-carboxamide 7 3-(2,4′-dichlorobenzhydryloxy)-N- (cyclopropylmethyl)azetidine-1-carboxamide 8 3-(2,4′-dichlorobenzhydryloxy)-N-(2,3- dihydrobenzofuran-5-yl-methyl)azetidine-1- carboxamide 9 3-(2,4′-dichlorobenzhydryloxy)-N-(2,5- dimethylfuran-3-yl-methyl)azetidine-1-carboxamide 10 3-(2,4′-dichlorobenzhydryloxy)-N-(2,3-Dihydro- benzo[1,4]dioxin-2-yl-methyl)azetidine-1- carboxamide 11 3-(2,4′-dichlorobenzhydryloxy)-N-(5-methyl- isoxazol-3-yl-methyl)azetidine-1-carboxamide 12 3-(2,4′-dichlorobenzhydryloxy)-N-[(R)-sec- butyl]azetidine-1-carboxamide 13 3-(2,4′-dichlorobenzhydryloxy)-N-(2- bromothiophen-3-yl-methyl)azetidine-1- carboxamide 14 3-(2,4′-dichlorobenzhydryloxy)-N-[(S)-sec-butyl] azetidine-1-carboxamide 15 3-(2,4′-dichlorobenzhydryloxy)-N-(thiophen-3-yl- methyl)azetidine-1-carboxamide 16 3-(2,4′-dichlorobenzhydryloxy)-N-(2- methoxyphenylmethyl)azetidine-1-carboxamide 17 3-(2,4′-dichlorobenzhydryloxy)-N-(2- furanylmethyl)azetidine-1-carboxamide 18 3-(2,4′-dichlorobenzhydryloxy)-N-(3- ethoxypropyl)azetidine-1-carboxamide 19 3-(2,4′-dichlorobenzhydryloxy)-N-(2- tetrahydrofuranylmethyl)azetidine-1-carboxamide 20 3-(2,4′-dichlorobenzhydryloxy)-N-(exo-2- norbornanyl)azetidine-1-carboxamide 21 3-(2,4′-dichlorobenzhydryloxy)-N-(1- phenylpropyl)azetidine-1-carboxamide 22 3-(2,4′-dichlorobenzhydryloxy)-N-[(R)-a- methylbenzyl]azetidine-1-carboxamide 23 3-(2,4′-dichlorobenzhydryloxy)-N-[(R)-1-(3- methoxyphenyl)ethyl]azetidine-1-carboxamide 24 3-(2,4′-dichlorobenzhydryloxy)-N-[(S)-1-(3- methoxyphenyl)ethyl]azetidine-1-carboxamide 25 3-(4,4′-dichlorobenzhydryloxy)-N-(1- adamantyl)azetidine-1-carboxamide 26 3-(4,4′-dichlorobenzhydryloxy)-N- (benzo[b]thiophen-2-yl-methyl)azetidine-1- carboxamide 27 3-(2,2′-dichlorobenzhydryloxy)-N-(1- adamantyl)azetidine-1-carboxamide 28 3-(4,4′-dibromobenzhydryloxy)-N-(tert- butyl)azetidine-1-carboxamide 29 3-(4,4′-dibromobenzhydryloxy)-N-(1- adamantyl)azetidine-1-carboxamide 30 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (tert-butyl)azetidine-1-carboxamide 31 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (n-propyl)azetidine-1-carboxamide 32 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (iso-propyl)azetidine-1-carboxamide 33 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (n-butyl)azetidine-1-carboxamide 34 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (sec-butyl)azetidine-1 carboxamide 35 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (ethyl propionate-3-yl)azetidine-1-carboxamide 36 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (ethyl 3-phenylpropionate-2-yl)azetidine-1- carboxamide 37 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (ethyl)azetidine-1-carboxamide 38 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- [(S)-a-methyl-benzyl]azetidine-1-carboxamide 39 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide 40 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (cyclopentyl)azetidine-1-carboxamide 41 3-(2,4′-dichlorobenzhydryloxy)-N-(2,2,4- trimethylpent-4-yl)azetidine-1-carboxamide 42 3-(2,4′-dichlorobenzhydryloxy)-N-(2-methylbut-2- yl)azetidine-1-carboxamide 43 3-[2-(trifluoromethyl)-2′-fluoro-4′- bromobenzhydryloxy]-N-(tert-butyl)azetidine- carboxamide 44 3-[2-(trifluoromethyl)-4′- (methylthio)benzhydryloxy]-N-(tert-butyl)azetidine- 1-carboxamide 45 3-[2-(trifluoromethyl)-4′- (methylthio)benzhydryloxy]-N-(iso- propyl)azetidine-1-carboxamide 46 3-[2-(trifluoromethyl)-4′- (methylthio)benzhydryloxy]-N-(sec-butyl)azetidine- 1-carboxamide 47 3-[2-(trifluoromethyl)-4′- (methylthio)benzhydryloxy]-N-(benzyl)azetidine-1- carboxamide 48 3-[2-(trifluoromethyl)-4-fluoro-4′- chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1- carboxamide 49 3-[2-(trifluoromethyl)-4-fluoro-4′- chlorobenzhydryloxy]-N-(iso-propyl)azetidine- carboxamide 50 3-[2-(trifluoromethyl)-4-fluoro-4′- chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1- carboxamide 51 3-[2-(trifluoromethyl)-4-fluoro-4′- chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1- carboxamide 52 3-[2-(trifluoromethyl)-4-fluoro-4′- chlorobenzhydryloxy]-N-(benzyl)azetidine-1- carboxamide 53 3-[2-(trifluoromethyl)benzhydryloxy]-N-(tert- butyl)azetidine-1-carboxamide 54 3-[2-(trifluoromethyl)benzhydryloxy]-N-(iso- propyl)azetidine-1-carboxamide 55 3-[2-(trifluoromethyl)benzhydryloxy]-N-(sec- butyl)azetidine-1-carboxamide 56 3-[2-(trifluoromethyl)benzhydryloxy]-N- (cyclohexyl)azetidine-1-carboxamide 57 3-[2-(trifluoromethyl)benzhydryloxy]-N- (benzyl)azetidine-1-carboxamide 58 N-(tert-butyl)-3-((4-(trifluoromethoxy)phenyl)(2- (trifluoromethyl)phenyl)methoxy)azetidine-1- carboxamide 59 3-[2-(trifluoromethyl)-4′- (trifluoromethoxy)benzhydryloxy]-N-(iso- propyl)azetidine-1-carboxamide 60 3-[2-(trifluoromethyl)-4′- (trifluoromethoxy)benzhydryloxy]-N-(sec- butyl)azetidine-1-carboxamide 61 3-[2-(trifluoromethyl)-4′- (trifluoromethoxy)benzhydryloxy]-N- (benzyl)azetidine-1-carboxamide 62 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (1-adamantyl)azetidine-1-carboxamide 63 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (cyclohexyl)azetidine-1-carboxamide 64 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (tert-amyl)azetidine-1-carboxamide 65 3-[2-(trifluoromethyl)-4′-methylbenzhydryloxy]-N- (1-adamantyl)azetidine-1-carboxamide 66 3-[2-(trifluoromethyl)-4′-methylbenzhydryloxy]-N- (tert-butyl)azetidine-1-carboxamide 67 3-[2-(trifluoromethyl)-4′-methylbenzhydryloxy]-N- (cyclohexyl)azetidine-1-carboxamide 68 3-[2-(trifluoromethyl)-4′-methoxybenzhydryloxy]-N- (1-adamantyl)azetidine-1-carboxamide 69 3-[2-(trifluoromethyl)-4′-methoxybenzhydryloxy]-N- (tert-butyl)azetidine-1-carboxamide 70 3-[2-(trifluoromethyl)-4′-fluorobenzhydryloxy]-N- (1-adamantyl)azetidine-1-carboxamide 71 3-[2-(trifluoromethyl)-4′-fluorobenzhydryloxy]-N- (tert-butyl)azetidine-1-carboxamide 72 3-[2-(trifluoromethyl)-4′-fluorobenzhydryloxy]-N- (cyclohexyl)azetidine-1-carboxamide 73 3-[2-(trifluoromethyl)-4′-chlorobenzhydryloxy]-N- (allyl)azetidine-1-carboxamide 74 3-[2-(trifluoromethyl)-4′- (methylthio)benzhydryloxy]-N-(1- adamantyl)azetidine-1-carboxamide 75 3-[2-(trifluoromethyl)-4′- (methylthio)benzhydryloxy]-N- (cyclohexyl)azetidine-1-carboxamide 76 N-(tert-butyl)-3-((4-(difluoromethoxy)phenyl)(2- (trifluoromethyl)phenyl)methoxy)azetidine-1- carboxamide 77 3-[2-(trifluoromethyl)-4′- (difluoromethoxy)benzhydryloxy]-N-(sec- butyl)azetidine-1-carboxamide 78 3-[2-(trifluoromethyl)-4′- (difluoromethoxy)benzhydryloxy]-N-(iso- propyl)azetidine-1-carboxamide 79 3-[2-(trifluoromethyl)-4′- (difluoromethoxy)benzhydryloxy]-N- (cyclohexyl)azetidine-1-carboxamide 80 3-[2-(trifluoromethyl)-4′- (difluoromethoxy)benzhydryloxy]-N- (allyl)azetidine-1-carboxamide 81 3-[2-(trifluoromethyl)-4′-fluorobenzhydryloxy]-N- (sec-butyl)azetidine-1-carboxamide 82 3-[2-(trifluoromethyl)-4′-fluorobenzhydryloxy]-N- (iso-propyl)azetidine-1-carboxamide 83 3-[2-(trifluoromethyl)-4′-fluorobenzhydryloxy]-N- [(S)-a-methylbenzyl]azetidine-1-carboxamide 84 3-[2-(trifluoromethyl)-2′-fluoro-4′-(1- piperidinyloxomethyl)benzhydryloxy]-N-(tert- butyl)azetidine-1-carboxamide 85 3-[2-(trifluoromethyl)-2′-fluorobenzhydryloxy]-N- (tert-butyl)azetidine-1-carboxamide - Formulations described herein may comprise a CB1 inhibitor and one or more excipients. In some aspects, described herein is a CB1 inhibitor co-formulated or co-administered with one or more agents that alkalinizes the tissues or body fluids in contact with the drug when disbursed. In some instances, the CB1 inhibitor is ANEB-001. A buccal delivery or sublingual delivery is in some instances particularly useful for this aspect of the methods described herein. Without being bound by theory, alkalinizing the solution in some instances resulting in the absorption of a CB1 inhibitor is hastened as the nitrogen in a CB1 inhibitor is less likely to exist in the protonated state, where the protonated state reduces its ability to traverse biologic membranes. The use of an alkaline formulation in combination with a CB1 inhibitor treatment in some instances facilitates the improved and faster absorption of the compound, especially in buccal or sublingual delivery. Accordingly, combinations of a CB1 inhibitor with appropriate alkalinizing compounds can either modify the protonation of a CB1 inhibitor or modify the buccal or sublingual tissue to promote improved transmission of a CB1 inhibitor into the bloodstream. Similarly, surfactants, including sodium dodecyl (lauryl) sulfate, polysorbates, laureths, Brijs, and benzalkonium chloride are predominantly water-soluble compounds that form associations (micelles) in aqueous solution. These associations in some instances enhance the sublingual or transbuccal permeation of a CB1 inhibitor into the bloodstream.
- The active compound (e.g., CB1 inhibitor) may be used in a pharmaceutical formulation including a pharmaceutically acceptable carrier. Accordingly, described herein are pharmaceutical formulations comprising a compound or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) is “acceptable” in the sense of being compatible with the other ingredients of the formulation, the activity of the CB1 inhibitor, and not deleterious to the patient. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art (see, e.g., Remington: The Science and Practice of Pharmacy, Twenty Second Edition, Pharmaceutical Press, 2015, hereby incorporated by reference). The pharmaceutical compositions of the CB1 inhibitors described herein may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- The formulations for CB1 inhibitors (e.g., ANEB-001), include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, suppository or rectal, and topical (including dermal, buccal, sublingual and intraocular) administration, although the most suitable route may depend upon the condition and disorder of the patient. In some instances, such formulations reverse one or more overdose symptoms. In one embodiment, the method comprises using a composition formulated for oral, sublingual, intranasal, absorbed by suppository, or parenteral administration comprising an effective amount of a CB1 inhibitor or a salt or polymorph thereof that is effective to reverse cannabinoid overdose or one or more symptoms of overdose in a patient. In some instances, formulations are fast-acting to reverse or ameliorate an overdose, such as in an emergency or rescue situation. In some instances, fast-acting formulations include methods of administration which deliver an effective amount of a formulation comprising a CB1 inhibitor to the bloodstream in a rapid manner. In some instances, a formulation is delivered in effective concentrations in no more than 1 hr, 30 min, 15 min, 10 min, 5 min, 2 min, 1 min, 30 sec or no more than 15 sec. In some instances, a formulation is delivered in effective concentrations in 10 sec-2 hr, 30 sec-2 hr, 1 min-2 hr, 10 sec-30 sec, 10 sec-1 min, 10-sec-2 min, or 15 min-2 hr. In some instances, a fast-acting formulation is delivered via intranasal, rectal, buccal, inhalation, or transdermal routes.
- The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound described herein (e.g., CB1 inhibitor) or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. In some instances, the carrier is a biopolymer, such as methyl cellulose.
- Formulations of CB1 inhibitors described herein for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. The a CB1 inhibitor compound can be a powder or granules, a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water liquid emulsion, or a water-in-oil liquid emulsion. a CB1 inhibitor may also be used as a bolus, electuary or paste.
- Pharmaceutical preparations which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricants, surface active agents or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in a conventional manner (Remington: The Science and Practice of Pharmacy, Twenty Second Edition, Pharmaceutical Press, 2015). Such compositions may comprise the active ingredient in a flavored basis such as with sucrose or other sweetener, and/or acceptable flavorings.
- Pharmaceutically acceptable carriers (e.g., excipients) for formulations described herein (e.g., with a CB1 inhibitor) may comprise one or more polymers. In some embodiments, the pharmaceutically acceptable carrier is a polymer. Examples of polymers suitable for oral, buccal, intranasal, transdermal, thin-film, suppository or other administration include biocompatible and biodegradable polymers. Further examples of biocompatible polymers include natural or synthetic polymers such as polystyrene, polylactic acid, polyketal, butadiene styrene, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, polyalkylcyanoacrylate, styrene-maleic anhydride copolymer, polyvinyl acetate, polyvinylpyridine, polydivinylbenzene, polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, polycaprolactone, poly(alkyl cyanoacrylates), poly(lactic-co-glycolic acid), and the like. In some instances, the carrier is Labrasol. In some instances, the carrier is methyl cellulose. In further embodiments, the pharmaceutically acceptable carrier comprises one or more biodegradable polymers. Use of biodegradable polymers provides the advantages of using a formulation that will eventually disintegrate, which facilitates release of the benzofuran compound and elimination of the carrier in vivo. However, benzofuran compounds can also be released from the matrix of non-biodegradable polymers as a result of gradual efflux from channels within the polymer matrix, including those formed by soluble materials included in the polymer matrix.
- Examples of biodegradable polymers include polylactide polymers include poly(D, L-lactide)s; poly(lactide-co-glycolide) (PLGA) copolymers; polyglycolide (PGA) and polydioxanone; caprolactone polymers; chitosan; hydroxybutyric acids; polyanhydrides and polyesters; polyphosphazenes; and polyphosphoesters. In some instances, the biodegradable polymer for use in the nanoparticles is poly-(D,L-lactide-co-glycolide).
- Functionalized poly (D,L-lactide)s can also be used as biodegradable polymers in the nanoparticles described herein. Examples of functionalized poly(D,L-lactide)s include poly(L-lactide), acrylate terminated; poly(L-lactide), amine terminated; poly(L-lactide), azide terminated; poly(L-lactide), 2-bromoisobutyryl terminated; poly(L-lactide), 2-bromoisobutyryl terminated; poly(L-lactide) 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentonate; poly(L-lactide)N-2-hydroxyethylmaleimide terminated; poly(L-lactide) 2-hydroxyethyl, methacrylate terminated; poly(L-lactide), propargyl terminated; or poly(L-lactide), thiol terminated.
- Other biodegradable polymers that can be used in the nanoparticles include AB-31-eblock copolymers such as poly(ethylene glycol) methyl ether-block-poly(D,L-lactide); poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) PEG; poly(ethylene glycol)-block-poly(.epsilon.-caprolactone) methyl ether PEG; and polypyrrole-block-poly(caprolactone). Further biodegradable polymers include ABA triblock copolymers such as polylactide-block-poly(ethylene glycol)-block-polylactide PLA; poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide); poly(lactide-co-caprolactone)-block-poly(ethylene glycol)-block-poly(lactide-co-caprolactone); polycaprolactone-block-polytetrahydrofuran-block-polycaprolactone; and polyglycolide-block-poly(ethylene glycol)-block-polyglycolide PEG.
- Biodegradable polymers also include various natural polymers. Examples of natural polymers include polypeptides including those modified non-peptide components, such as saccharide chains and lipids; nucleotides; sugar-based biopolymers such as polysaccharides; cellulose; carbohydrates and starches; dextrans; lignins; polyamino acids; adhesion proteins; lipids and phospholipids (e.g., phosphorylcholine). In some embodiments, the polymer is a cellulose derivative such as hydroxypropyl methylcellulose polymers. Hydroxypropyl methyl cellulose (HPMC) is a non-ionic cellulose ether made through a series of chemical processes, with the natural polymer cellulose as the raw material. The product is a non-ionic cellulose ether in the shape of white powder, odorless and tasteless. HPMC is also known as hypromellose, is a methylcellulose modified with a small amount of propylene glycol ether groups attached to the anhydroglucose of the cellulose.
- Useful pharmaceutical compositions also, optionally, include solubilizing agents to aid in the solubility of a CB1 inhibitor described herein. The term “solubilizing agent” generally includes agents that result in formation of a micellar solution or a true solution of the agent. Certain acceptable nonionic surfactants, for example polysorbate 80, are useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g.,
polyethylene glycol 400, and glycol ethers. The solubilizing agent can be selected from the group consisting of a cyclodextrin, a glycol, a glycerol, and combinations thereof. In some embodiments, the solubilizing agent includes a cyclodextrin. For example, the solubilizing agent can be selected from the group consisting of a β-cyclodextrin derivative, a γ-cyclodextrin, and combinations thereof. In some embodiments, the solubilizing agent includes a hydroxy alkyl-γ-cyclodextrin. The solubilizing agent can include a β-cyclodextrin selected from the group consisting of a hydroxy alkyl-β-cyclodextrin, a sulfoalkyl ether-β-cyclodextrin, and combinations thereof. In some embodiments, the solubilizing agent includes hydroxypropyl-β-cyclodextrin. In some embodiments, the cyclodextrin can include an α-cyclodextrin, β-cyclodextrin derivative, a δ-cyclodextrin derivative, a γ-cyclodextrin, or a combination derivative thereof. For example, the solubilizing agent can include a cyclodextrin. The solubilizing agent can include a β-cyclodextrin derivative, a γ-cyclodextrin, or a mixture thereof. For example, the solubilizing agent can include a hydroxy alkyl-γ-cyclodextrin. In some embodiments, the solubilizing agent includes a β-cyclodextrin including at least one of a hydroxy alkyl-β-cyclodextrin (e.g., hydroxypropyl-β-cyclodextrin) or a sulfoalkyl ether-β-cyclodextrin (e.g., sulfobutyl ether-β-cyclodextrin). For example, the liquid the solubilizing agent can include hydroxypropyl-β-cyclodextrin. In some embodiments, the cyclodextrin is CAVASOL® W7 HP (hydroxypropyl-β-cyclodextrin). In some embodiments, the cyclodextrin is KLEPTOSE® HP (hydroxypropyl-β-cyclodextrin). In some embodiments, the cyclodextrin is CAVAMAX® W7 (β-cyclodextrin). In some embodiments, the cyclodextrin is CAPTISOL® (sulfoalkyl ether-β-cyclodextrin). In some embodiments, the cyclodextrin is CAVASOL® W7 M (methyl-β-cyclodextrin). In some embodiments, the cyclodextrin is CAVASOL® W8 HP (hydroxypropyl-γ-cyclodextrin). In some embodiments, the cyclodextrin is CAVAMAX® W8 (γ-cyclodextrin). In some embodiments, the cyclodextrin is CAVAMAX® W6 (α-cyclodextrin). - Furthermore, useful pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
- Additionally, useful compositions also, optionally, include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
- Still other useful compositions include one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
- In some embodiments, the CB1 inhibitors as described herein are formulated into an injectable composition. In some embodiments, the injectable composition comprises a CB1 inhibitor, or the pharmaceutical composition described herein, an opioid antagonist, and a benzodiazepine antagonist. In some embodiments, the benzodiazepine antagonist is flumazenil. In some embodiments, the opioid antagonist is naloxone or naltrexone. In some embodiments, the injectable composition is formulated in a single dose injectable device.
- CB1 inhibitors described herein may be formulated with one or more pharmaceutically active agents. In some embodiments described herein, the CB1 inhibitor is formulated with naloxone or an opioid antidote. In some instances, an opioid antidote or opioid antagonist includes nalmefene or nalorphine. These can be administered with a Luer-Jet or Luer Lock Prefilled Syringe of 2 mg/2 mL naloxone hydrochloride. The IMS Luer-Jet™ system is a needleless prefilled emergency syringe. In some instances, the CB1 inhibitor is administered with flumazenil or other benzodiazepine antagonist. And similarly, in some instances the CB1 inhibitor is administered with both an opioid and a benzodiazepine antagonist in a single formulation. In another aspect, devices and methods described herein provide an overdose rescue pen that an emergency responder or others can use to treat an unresponsive person suspected of a drug overdose where the drug(s) in question are unknown. Said pen in some instances includes one or more of a narcotic antagonist, a benzodiazepine antagonist, and a cannabinoid antagonist such as ANEB-001, or a CB1 neutral antagonist. Formulations described herein are in some instances are configured for IV, IM, subcutaneous or other injection, or for intranasal delivery. Intranasal formulations comprising certain polymers in some instances increase the residence time of active compounds on the mucosal membranes. Similarly, the pH of the formulation and/or the ionization state of the active compound(s) are in some instances taken into consideration for more effective transport across the nasal mucosa.
- A formulation described herein may comprise a CB1 inhibitor and one or more active agents. In some instances, a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (w/w). In some instances, a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (molar ratio). In some instances, the CB1 inhibitor is administered with the one or more active agents as a single formulation. In some instances, the CB1 inhibitor is administered with the one or more active agents as two or more formulations. A CB1 inhibitor may be administered in combination with one or more active agents. In some instances, the active agent is an anxiolytic agent. In some instances, the active agent is a cannabinoid. In some instances, the cannabinoid is cannabidiol (CBD). In some instances, the active agent is CBG (Cannabigerol), CBD (Cannabidiol), CBC (Cannabichromene), CBGV (Cannabigerivarin), THCV (Tetrahydrocannabivarin), CBDV (Cannabidivarin), or CBCV (Cannabichromevarin).
- Formulations comprising a CB1 inhibitors (such as ANEB-001) may comprise one or more active agents (e.g., CBD). In some instances, a formulation comprises about 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg, 60 mg, 75 mg, 100 mg, 125 mg, or 150 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, 150, 300, 500, or 800 mg of CBD. Formulations comprising a CB1 inhibitors (such as ANEB-001) may comprise one or more active agents (e.g., CBD). In some instances, a formulation comprises about 10-150 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, or 150 mg of CBD. In some instances, a formulation comprises about 50-150 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, 150, 300, 500, or 800 mg of CBD. In some instances, a formulation comprises about 60-120 mg of ANEB-001 and 0.5, 1, 2, 5, 10, 20, 50, 75, 100, or 150, 300, 500, or 800 mg CBD. In some instances, a formulation comprises about 10-150 mg of ANEB-001 and 5-800 mg of CBD. In some instances, a formulation comprises about 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg, 60 mg, 75 mg, 100 mg, 125 mg, or 150 mg of ANEB-001 and 5-800 mg of CBD.
- Compositions and formulations described herein may be administered as single or multiple doses. In one aspect, described herein are methods of using a CB1 inhibitor (e.g., ANEB-001) as a single dose, one-time treatment for overdose of THC or SCs, or both. The overdose can also be from consumption of cannabis, a synthetic cannabinoid, or any compound that is an agonist at the CB1 receptor. In some instances, methods described herein include treatments to children who inadvertently consume cannabis or cannabinoid edibles. In related aspects, any suspected overdose patient that presents as mentally disoriented or psychotic or cannot articulate the nature of their condition or the substances that have been ingested or administered can be treated with a CB1 inhibitor. In some instances, a THC or SC overdose is treated by administration of a CB1 inhibitor and one or more active agents (e.g., opioid antagonist, benzodiazepine antagonist, cannabinoid, or other active agent). In some instances, the CB1 inhibitor and one or more active agents are administered as a single formulation.
- Described herein are methods of treating patients for one or more of the following: a CB1 antagonist (e.g., ANEB-001) formulated for oral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, and intranasal administration. In some instances, a CB1 inhibitor is formulated in an injector pen for on-site administration to an overdose patient as well as the use of a CB1 inhibitor by emergency responders to treat THC or SC overdose outside of the hospital. The methods described herein also include the use of a CB1 inhibitor to treat cannabinoid hyperemesis syndrome and the use of various formulations and administration methods for that treatment, including the use of a CB1 inhibitor in suppository form to treat cannabinoid hyperemesis syndrome. In some instances, a CB1 inhibitor is formulated for rapid nasal injection.
- In some instances, CB1 antagonists prevent, treat or reduce the severity of various medical conditions and symptoms, including, but not limited to obesity, appetite disorder, another metabolic disorder, drug addiction and/or mental illness. In some instances, CB1 antagonists are used for the treatment of: addiction, alcoholism, Alzheimer's disease, anorexia nervosa, anxiety disorder, appetite disorders, attention deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, cancer, cardiovascular disorders, central nervous system disease, cerebral ischemia, cerebral apoplexy, chemotherapy induced emesis, cocaine addiction, cognitive disorder, dementia, demyelination related disorders, diabetes, diabetic neuropathy, diarrhea, drug dependence, dystonia, eating disorder, emesis, epilepsy, female sexual dysfunction, functional bowel disorder, gastrointestinal disorders, gastric ulcers, generalized anxiety disorder, glaucoma, headache, Huntington's disease, impulse control disorders inflammation, irritable bowel syndrome, male sexual dysfunction, major depressive disorder, memory disorders menopause, migraine, muscle spasticity, multiple sclerosis, myalgia, nausea, neuralgia, neurodegenerative disorders, neuroinflammatory disorders, neuropathic pain, obesity, obsessive compulsive disorder, osteoarthritis, pain, panic disorder, Parkinson's disease, plaque sclerosis, premature ejaculation, premenstrual syndrome, psychosexual disorder, psychosis, rheumatoid arthritis, septic shock, schizophrenia, sexual disorders, sleep disorder, spinal cord injury, stroke, Tourette's syndrome, traumatic brain injury, tremor, urinary incontinence, and viral encephalitis.
- The methods described herein include pre-exposure prophylaxis treatments. The long term effects of CB1 antagonism, which in some instances includes anhedonia, potentially makes them unsuitable for chronic use. However, in the same way an alcoholic might consume disulfiram before entering a situation when tempted to consume alcohol, one can take a CB1 antagonist, such as ANEB-001, before encountering a situation where they may likely be exposed to or tempted to ingest THC or SCs or both. Similarly, in some instances, a CB1 inhibitor is used to prevent effects from second hand smoke from marijuana. The method of using a CB1 inhibitor in some instances includes use by someone who wishes to gain acceptance to a situation or group by smoking marijuana or SCs, but also wants to remain mentally alert, such as during an undercover police or law enforcement investigation.
- In various embodiments, the method reduces the subject's ability to experience euphoria after inhaling or consuming Cannabis or a synthetic cannabinoid.
- The methods described herein include use of a CB1 inhibitor to treat cannabinoid hyperemesis syndrome. In one aspect, the use of the CB1 inhibitor in a suppository form is used to treat cannabinoid hyperemesis syndrome.
- Methods described herein may be used to treat a patient with a known or suspected acute drug overdose. In some instances, this is determined by the judgement of a qualified healthcare professional or emergency medical technician. In some instances, a lack of or reduced response to prior overdose treatments indicates a potential cannabinoid overdose. Such a patient is in some instances subsequently treated using the CB1 inhibitors described herein. In some instances, a patient is treated with a prior treatment comprising administration of an opiate antagonist, activated charcoal, or emetic. In some instances, the prior treatment is orogastric lavage or whole bowel irrigation.
- A CB1 inhibitor may be administered after confirmation of a cannabinoid overdose by one or more testing methods. In some instances, the testing method is a blood test. In some instances, the blood test comprises determination of the cannabinoid (or synthetic cannabinoid) plasma concentration. In some instances, a patient is administered a CB1 inhibitor (e.g., ANEB-001) when his or her cannabinoid plasma concentration is at least 25, 50, 125, 150, 175, 200, 225, 250, 275, 300, 325, or at least 350 ug/L. In some instances, a patient is administered a CB1 inhibitor (e.g., ANEB-001) when his or her cannabinoid plasma concentration is 25-300 ug/L, 50-300 ug/L, 75-300 ug/L, 100-300 ug/L, 125-300 ug/L, or 200-400 ug/L.
- A CB1 inhibitor (e.g., ANEB-001) may be administered to obtain diagnostic information about whether a patient is suffering from a cannabinoid or synthetic cannabinoid overdose. If a patient's mental state fails to improve upon administration of a CB1 inhibitor, other etiologies of confusion or altered mental state in some instances are considered, including intoxication with other substances, psychiatric illnesses, metabolic conditions and inflammatory, infectious or traumatic conditions of the brain. Treatment with a CB1 inhibitor in some instances is used for diagnostic purposes.
- A CB1 inhibitor may be administered in combination with one or more active agents. In some instances, the active agent is an anxiolytic agent. In some instances, the active agent is a cannabinoid. In some instances, the cannabinoid is cannabidiol (CBD). In some instances, the active agent is CBG (Cannabigerol), CBD (Cannabidiol), CBC (Cannabichromene), CBGV (Cannabigerivarin), THCV (Tetrahydrocannabivarin), CBDV (Cannabidivarin), or CBCV (Cannabichromevarin).
- In some instances, a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (w/w). In some instances, a CB1 inhibitor is administered with an active agent in a 0.1:1, 0.2:1, 0.5:1, 1:1, 1.5:1, 2:1, 5:1, or 10:1 (molar ratio). In some instances, the CB1 inhibitor is administered with the one or more active agents as a single formulation. In some instances, the CB1 inhibitor is administered with the one or more active agents as two or more formulations.
- After administration of a CB1 inhibitor (e.g., ANEB-001) described herein, a patient may be monitored for improvement. Monitoring in some instances comprises heart rate monitoring, respiration monitoring, or measures such as patient cognitive function or behavior. In some instances, monitoring comprises patient-reported feelings or answers to verbal or written interrogatories.
- CB1 inhibitors may be dosed in various amounts. In some instances, the CB1 inhibitor is dosed at about 1, 2, 5, 10, 25, 40, 50, 75, 90, 100, or about 150 mg. In some instances, the CB1 inhibitor is dosed at no more than 1, 2, 5, 10, 25, 40, 50, 75, 90, 100, or no more than 150 mg. In some instances, the CB1 inhibitor is dosed at least at 1, 2, 5, 10, 25, 40, 50, 75, 90, 100, or at least 150 mg. In some instances, the CB1 inhibitor is dosed at 1-200, 1-100, 1-50, 2-100, 5-100, 10-150, 10-200, 20-120, 50-125, 50-200, or 75-150 mg. In some instances, the CB1 inhibitor is dosed orally. In some instances, the CB1 inhibitor is dosed rectally.
- CB1 inhibitors (such as ANEB-001) may be administered in an oral dosage form. In some instances, ANEB-001 is dosed (oral) at 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg or more, typically taken once, or once daily. ANEB-001 at 30 mg/kg to 10 mg/kg i.p. is in some instances administered subcutaneously. Similarly, a single dose of ANEB-001 i.p. at 0.1 mg/kg is in some instances used. For example, a CB1 inhibitor test employing forty-two male volunteers to receive one of three oral drug regimens, 40 mg daily for 15 days, placebo for 14 days, then 90 mg on
day 15, or placebo for 15 days can be used test effectiveness. Oral dosages of ANEB-001 are in some instances selected from one or more of 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, or 40 mg once daily. In some instances, oral dosages of ANEB-001 are about 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 40 mg, 50 mg, 60 mg, 75 mg, 90 mg, or about 100 mg. While preferably delivered as an acute therapy, ANEB-001 is administered daily for up to 2, 4, 6, 10, 12, 15, 20, 25, or up to 28 days. In some instances, ANEB-001 is administered as a single acute dosage. CB1 inhibitors (such as ANEB-001) may be administered with one or more active agents, such as CBD. In some instances, a CB1 inhibitor is administered with 0.5, 1, 2, 5, 10, 20, 50, 75, 100, or 150 mg of CBD. - In one aspect, the present disclosure provides a method of treating known or suspected acute drug overdose reaction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of CB1 inhibitor, or the pharmaceutical composition as described herein.
- In some embodiments, the subject shows signs of an acute cannabinoid overdose. In some embodiments, the acute cannabinoid overdose is caused by a compound from the Cannabis genus. In some embodiments, the acute cannabinoid overdose is caused by a synthetic cannabinoid. In some embodiments, the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids. In some embodiments, the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids. In some embodiments, the synthetic cannabinoid is capable of binding to the Cannabinoid (CB1) receptor. In some embodiments, the subject shows signs of cannabinoid hyperemesis syndrome.
- In some embodiments, the method further comprising treatment for drug overdose prior to treatment with the CB1 inhibitor. In some embodiments, the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic.
- In another aspect, the present disclosure provides a method of using the CB1 inhibitor, or the pharmaceutical composition as described herein, comprising administering a therapeutically effective amount of the CB1 inhibitor prior to exposure to a cannabinoid. In some embodiments, the cannabinoid is tetrahydrocannabinol (THC).
- In another aspect, the present disclosure provides a method of treating a subject suspected of a drug overdose, comprising administering a therapeutically effective amount of the CB1 inhibitor to the subject and monitoring said subject for reduced symptoms associated with overdose. In some embodiments, the monitoring comprises monitoring heart rate or respiration.
- In various embodiments of the methods described herein, the method further comprising a diagnostic test prior to treatment with the CB1 inhibitor. In some embodiments, the diagnostic test is a blood test. In some embodiments, the subject has a cannabinoid plasma concentration of at least 25 μg/L. In some embodiments, the diagnostic test is a blood test. In some embodiments, the subject has a cannabinoid plasma concentration of at least 50 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 25 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 50 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 75 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 100 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 150 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 200 μg/L to 350 μg/L.
- In various embodiments of the methods as described here, the amount of the CB1 inhibitor is between about 1 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 5 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 10 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 15 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 20 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 25 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 30 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 35 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 40 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 45 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 50 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 75 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 100 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 125 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 150 mg to about 200 mg. In another embodiment, the amount of the CB1 inhibitor is between about 175 mg to about 200 mg. In various embodiments of the methods as described here, the amount of the CB1 inhibitor is between about 1 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 5 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 10 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 15 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 20 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 25 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 30 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 35 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 40 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 45 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 50 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 75 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 100 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 125 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 150 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is between about 175 mg to about 300 mg. In another embodiment, the amount of the CB1 inhibitor is 25-500, 25-400, 25-300, 25-250, 25-200, 25-150, 25-100, or 25-75 mg. In another embodiment, the amount of the CB1 inhibitor is 50-500, 50-400, 50-300, 50-250, 50-200, 50-150, 50-100, or 50-75 mg. In another embodiment, the amount of the CB1 inhibitor is 75-500, 75-400, 75-300, 75-250, 75-200, 75-150, 75-100, or 75-125 mg. In another embodiment, the amount of the CB1 inhibitor is 100-500, 100-400, 100-300, 100-250, 100-200, 100-150, 100-125 mg.
- In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 10 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 15 minutes. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 45 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 20 minutes. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in 5-60, 5-45, 5-30, 5-25, 5-20, 5-15, 5-10, 10-60, 10-120, 10-30, 20-60, 20-120, 50-120, 60-120, or 90-120 minutes.
- In various embodiments of the methods described herein, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 50 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 20 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 10 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 5 minutes after oral administration.
- In various embodiments of the methods described herein, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 50 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 30 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 20 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 10 minutes after oral administration. In another embodiment, the amount of CB1 inhibitor in the bloodstream of the subject reaches at least 150 ng/mL within 5 minutes after oral administration.
- In some instances, CB1 inhibitor is dosed to provide a Tmax of no more than 5, 4, 3, 2.5, 2.25, 2, 1.75, 1.5, 1.25, 1, 0.75, 0.5, or 0.25 hours. In some instances, CB1 inhibitor is dosed to provide a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, CB1 inhibitor dosed at 100-200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, CB1 inhibitor dosed at 25-250 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, CB1 inhibitor dosed at no more than 200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, CB1 inhibitor dosed at no more than 150 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, CB1 inhibitor dosed at no more than 100 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- In one aspect, the present disclosure provides a method of treating known or suspected acute drug overdose reaction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide, or the pharmaceutical composition as described herein.
- In some embodiments, the subject shows signs of an acute cannabinoid overdose. In some embodiments, the acute cannabinoid overdose is caused by a compound from the Cannabis genus. In some embodiments, the acute cannabinoid overdose is caused by a synthetic cannabinoid. In some embodiments, the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids. In some embodiments, the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids. In some embodiments, the synthetic cannabinoid is capable of binding to the Cannabinoid (CB1) receptor. In some embodiments, the subject shows signs of cannabinoid hyperemesis syndrome.
- In some embodiments, the method further comprising treatment for drug overdose prior to treatment with the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide. In some embodiments, the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic.
- In another aspect, the present disclosure provides a method of using the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide, or the pharmaceutical composition as described herein, comprising administering a therapeutically effective amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide prior to exposure to a cannabinoid. In some embodiments, the cannabinoid is tetrahydrocannabinol (THC).
- In another aspect, the present disclosure provides a method of treating a subject suspected of a drug overdose, comprising administering a therapeutically effective amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide to the subject and monitoring said subject for reduced symptoms associated with overdose. In some embodiments, the monitoring comprises monitoring heart rate or respiration.
- In various embodiments of the methods described herein, the method further comprising a diagnostic test prior to treatment with the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide. In some embodiments, the diagnostic test is a blood test. In some embodiments, the subject has a cannabinoid plasma concentration of at least 25 μg/L. In some embodiments, the diagnostic test is a blood test. In some embodiments, the subject has a cannabinoid plasma concentration of at least 50 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 25 μg/L to 350 g/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 50 g/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 75 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 100 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 150 μg/L to 350 μg/L. In some embodiments, the subject has a cannabinoid plasma concentration of about 200 μg/L to 350 μg/L.
- In various embodiments of the methods as described here, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 1 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 5 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 10 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 15 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 20 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 25 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 30 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 35 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 40 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 45 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 50 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 75 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 100 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 125 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 150 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is between about 175 mg to about 200 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 25-500, 25-400, 25-300, 25-250, 25-200, 25-150, 25-100, or 25-75 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 50-500, 50-400, 50-300, 50-250, 50-200, 50-150, 50-100, or 50-75 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 75-500, 75-400, 75-300, 75-250, 75-200, 75-150, 75-100, or 75-125 mg. In another embodiment, the amount of the (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is 100-500, 100-400, 100-300, 100-250, 100-200, 100-150, 100-125 mg.
- In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 10 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 15 minutes. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 45 minutes. In another embodiment, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 20 minutes. In various embodiments, the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in 5-60, 5-45, 5-30, 5-25, 5-20, 5-15, 5-10, 10-60, 10-120, 10-30, 20-60, 20-120, 50-120, 60-120, or 90-120 minutes.
- In various embodiments of the methods described herein, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 50 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 20 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 10 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within 5 minutes after oral administration.
- In various embodiments of the methods described herein, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 50 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 40 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 30 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 20 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 10 minutes after oral administration. In another embodiment, the amount of (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide in the bloodstream of the subject reaches at least 150 ng/mL within 5 minutes after oral administration.
- In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is dosed to provide a Tmax of no more than 5, 4, 3, 2.5, 2.25, 2, 1.75, 1.5, 1.25, 1, 0.75, 0.5, or 0.25 hours. In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide is dosed to provide a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at 100-200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at 25-250 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at no more than 200 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at no more than 150 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr. In some instances, (R)-N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide dosed at no more than 100 mg provides a Tmax of 0.1-5, 0.1-4, 0.1-3, 0.1-2, 0.1-1.5, 0.1-1, 0.25-3, 0.25-2, 0.25-1.5, 0.25-1, 0.5-3, 0.5-2.5, 0.5-2, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, or 0.75 hr.
- In some embodiments, the CB1 inhibitor (e.g., ANEB-001) has a half-life of at least 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or at least 24 hours. In some embodiments, the CB1 inhibitor has a half-life of 2-24, 2-12, 2-8, 4-24, 4-16, 4-12, 4-8, 6-12, 6-16, 6-10, 8-24, 8-16, 8-12, 12-24, or 12-48 hours.
- In some embodiments, the CB1 inhibitor (e.g., ANEB-001) has a reduced seizure liability relative to other CB1 inhibitors. In some embodiments, ANEB-001 has a reduced seizure liability relative to other CB1 inhibitors. In some embodiments, ANEB-001 has a reduced seizure liability relative to other CB1 inhibitors. In some embodiments, ANEB-001 has a reduced seizure liability relative to drinabant, taranabant, or rimonabant. In some instances, seizure liability is reduced by 10, 20, 50, 75, 100, 200, 400, 500, 1000, or 2000 percent.
- In some instances, the CB1 inhibitor (e.g., ANEB-001) does not inhibit one or more P450 enzymes. In some embodiments, the CB1 inhibitor is metabolized by one or more of CYP3A4, CYP2C9, CYP2C19, CYP1A2, CYP2E1, CYP2D6, and CYP2A6. In some instances, the CB1 inhibitor does not inhibit CYP3A4. In some embodiments, the CB1 inhibitor comprises an IC50 of individual CYP450s of less than 100, 80, 70, 60, 50, 40, 30, 20, or 10 micromolar in human liver microsomes.
- As used herein, the term “about” is intended to qualify the numerical values which it modifies, denoting such a value as variable within a range. When no range, such as a margin of error or a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean the greater of the range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, considering significant figures, and the range which would encompass the recited value plus or minus 20%.
- As used herein, the term “agonist” refers to a moiety that interacts with, and activates, a receptor and thereby initiates a physiological or pharmacological response characteristic of that receptor.
- As used herein, the term “antagonist” refers to a compound that binds to a receptor, such as CB1, but which does not activate the intracellular response(s) initiated by an active agonist compound of the receptor. The antagonist can thereby inhibit the intracellular responses that would be elicited by an agonist or partial agonist if present. An antagonist does not diminish the baseline intracellular response in the absence of an agonist or partial agonist. The term “inverse agonist” refers to a moiety that binds to the endogenous form of the receptor or to the constitutively activated form of the receptor and which inhibits the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of an agonist or partial agonist. It is noted that under certain conditions a compound can behave like an antagonist while under other conditions it can behave as an inverse agonist. Functionally, both an antagonist and an inverse agonist can block and/or reverse the effects of an agonist or partial agonist. In some instances, a CB1 inhibitor includes compounds which act as antagonists or inverse agonists. In some instances, the term “neutral antagonist” is an antagonist that does not change the baseline response level of the receptor when it binds to receptor. In some instances, a neutral antagonist comprises ANEB-001.
- As used herein, symptom(s) of cannabinoid overdose is “apparent” or “suspected” when, in the judgment of a trained healthcare provider or emergency responder, the patient has one or more symptom(s) associated with a cannabinoid overdose. In some instances, a cannabinoid overdose is suspected from an absence or reduced response to other overdose related medical treatments (e.g., opioid antagonists, antipsychotics, or other overdose treatment).
- As used herein, reversal of symptom(s) of cannabinoid overdose is “apparent” when, in the judgment of a trained healthcare provider or emergency responder, the symptom(s) have been reduced or abated to a noticeable degree. Such a provider may use any appropriate measure to quantify the reversal of symptom(s), e.g., a visual analog scale for self-reporting, a heart rate monitor for tachycardia, an improved affect, etc. “Apparent” reversal of symptom(s) includes, but need not extend to, complete reversal.
- As used herein, the term “cannabinoid” is synonymous with “cannabinoid receptor agonist” and refers to a compound which binds to and activates a cannabinoid receptor. The term includes both natural and synthetic compounds.
- As used herein, the term “synthetic cannabinoid” (“SC”) means a non-naturally-occurring cannabinoid. Most SCs are lipid-soluble, non-polar, small molecules that are fairly volatile, and often have a side-chain of 5-9 saturated carbon atoms. SCs are associated with psychotropic activity from binding CB1 receptors. There are at least five major structural categories for synthetic cannabinoids: classical cannabinoids, non-classical cannabinoids, hybrid cannabinoids, aminoalkylindoles (and their analogues), and eicosanoids. Classical cannabinoids are analogs of THC that are based on a dibenzopyran ring; examples include nabilone, dronabinol, and the (−)-1,1-dimethylheptyl analog of 11-hydroxy-A8-tetrahydrocannabinol. Non-classical cannabinoids include cyclohexylphenols such as cannabicyclohexanol. Hybrid cannabinoids have a combination of classical and non-classical cannabinoid structural features. Aminoalkylindoles are structurally dissimilar to THC and include naphthoylindoles such as 1-pentyl-3-(1-naphthoyl)indole, phenylacetylindoles such as 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250), and benzoylindoles such as 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; they are the most common SCs found in SC blends due to relative ease of synthesis. Other compounds structurally similar to aminoalkylindoles include naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles/benzoylindoles, tetramethylcyclopropylindoles, adamantoylindoles, indazole carboxamides, indolecarboxylates, and quinolinyl esters. Eicosanoid SCs are analogs of endocannabinoids such as anandamide. In some instances, SCs are CB1 activators, such as agonists.
- As used herein, the term “cannabinoid receptor antagonist” or “CB1 antagonist” refers to a compound that binds to and blocks or dampens the normal biological function of the CB1 receptor and its signaling. This activity can occur in the presence of a natural or synthetic agonist or partial agonist. The term includes cannabinoid receptor antagonists that are selective or nonselective for the CB1 receptor subtype.
- As used herein, “active agent” is used to indicate a chemical entity which has biological activity. In certain embodiments, an “active agent” is a compound having pharmaceutical utility. For example an active agent may be an anti-cancer therapeutic.
- As used herein, “modulation” refers to a change in activity as a direct or indirect response to the presence of a chemical entity as described herein, relative to the activity of in the absence of the chemical entity. The change may be an increase in activity or a decrease in activity, and may be due to the direct interaction of the compound with the target or due to the interaction of the compound with one or more other factors that in turn affect the target's activity. For example, the presence of the chemical entity may, for example, increase or decrease the target activity by directly binding to the target, by causing (directly or indirectly) another factor to increase or decrease the target activity, or by (directly or indirectly) increasing or decreasing the amount of target present in the cell or organism.
- As used herein, “therapeutically effective amount” of a chemical entity described herein refers to an amount effective, when administered to a human or non-human subject, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prevention of disease.
- “Treating” or “treatment” encompasses administration of
Compound 1, or a pharmaceutically acceptable salt thereof, to a mammalian subject, particularly a human subject, in need of such an administration and includes (i) arresting the development of clinical symptoms of the disease, such as cancer, (ii) bringing about a regression in the clinical symptoms of the disease, such as cancer, and/or (iii) prophylactic treatment for preventing the onset of the disease, such as cancer. - As used herein, a “pharmaceutically acceptable” component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochlorate, carbonate, phosphate, hydrogenphosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, malonate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, gluconate, methanesulfonate, Tris (hydroxymethyl-aminomethane), p-toluenesulfonate, propionate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, oxalate, pamoate, and alkanoate such as acetate, HOOC—(CH2)n—COOH where n is 0-4, and like salts. Other salts include sulfate, methanesulfonate, bromide, trifluoroacetate, picrate, sorbate, benzilate, salicylate, nitrate, phthalate or morpholine. Pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium.
- In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare non-toxic pharmaceutically acceptable addition salts.
- As used herein, “subject” refers to a mammal that has been or will be the object of treatment, observation or experiment. The methods described herein can be useful in both human therapy and veterinary applications. In some embodiments, the subject is a human.
- “Prodrugs” described herein include any compound that becomes
Compound 1 when administered to a subject, e.g., upon metabolic processing of the prodrug. Similarly, “pharmaceutically acceptable salts” includes “prodrugs” of pharmaceutically acceptable salts. Examples of prodrugs include derivatives of functional groups, such as a carboxylic acid group, inCompound 1. Exemplary prodrugs of a carboxylic acid group include, but are not limited to, carboxylic acid esters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters, and aryloxyalkyl esters. Other exemplary prodrugs include lower alkyl esters such as ethyl ester, acyloxyalkyl esters such as pivaloyloxymethyl (POM), glycosides, and ascorbic acid derivatives. Other exemplary prodrugs include amides of carboxylic acids. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985. - A “solvate” is formed by the interaction of a solvent and a compound. The term “compound” is intended to include solvates of compounds. Similarly, “pharmaceutically acceptable salts” includes solvates of pharmaceutically acceptable salts. Suitable solvates are pharmaceutically acceptable solvates, such as hydrates, including monohydrates and hemi-hydrates. Also included are solvates formed with the one or more crystallization solvents.
- Pharmaceutically acceptable forms of the compounds recited herein include pharmaceutically acceptable salts, chelates, non-covalent complexes, prodrugs, and mixtures thereof.
- A “chelate” is formed by the coordination of a compound to a metal ion at two (or more) points. The term “compound” is intended to include chelates of compounds. Similarly, “pharmaceutically acceptable salts” includes chelates of pharmaceutically acceptable salts.
- A “non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding). Such non-covalent complexes are included in the term “compound”. Similarly, pharmaceutically acceptable salts include “non-covalent complexes” of pharmaceutically acceptable salts.
- When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and sub combinations of ranges and specific embodiments therein are intended to be included.
- As used herein, “significant” refers to any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p<0.05.
- Reversal of THC-induced hypolocomotion in mice: Six C57 mice (Charles River, Wilmington, MA) were administered A9-tetrahydrocannabinol (THC) 3 mg/kg ip, 10 min pre-test. The mice exhibited reduced locomotor activity when placed in automated locomotor activity cages for 15 min. In this apparatus, four qualitatively different measures of locomotor activity are automatically scored. In a preliminary screen to identify active CB1 antagonists, ANEB-001 (compound 1) given orally at a dose of 30 mg/kg and 30 min pre-test, significantly reversed the action of THC on the total active time parameter of these locomotor measures (
FIG. 1 ). The magnitude of the effect is similar to that elicited by rimonabant given at 3 mg/kg po, and given 30 min pre-test. - Repeated dose (28 day) toxicity studies were conducted using ANEB-001 in two species, rat and primate, selected on the basis of acceptable bioavailability and comparison of metabolite profiles with those in human liver microsomes. No adverse effects were observed at the highest dose tested in the rat, therefore the no observed adverse effect level in the rat was 75 mg/kg/day. Dose levels of 75 mg/kg/day were associated with hepatic changes consistent with an adaptive response to repeated administration of high doses of ANEB-001 to rats.
- In repeat dose (28 day) toxicity studies no adverse effects were observed at the highest dose level studied in the cynomolgus monkey, 160 mg/kg/day.
- Human subjects were assigned to six different dosage groups of ANEB-001. Groups assigned to receive dosages of 1 mg, 5 mg, 25 mg, 100 mg, or 200 mg had six subjects each, and the 150 mg dosage group had four subjects. ANEB-001 was administered orally to subjects in each group, and the plasma concentration of ANEB-001 in each subject was measured as a function of time after dosing (
FIG. 2 ). ANEB-001 had a Tmax of approximately 1-1.6 hours, and a terminal elimination half-life up to 19 days. - A patient admitted to the emergency room is diagnosed with acute THC poisoning from overconsumption of cannabinoid products, such as edibles. The patient is administered a 75 mg oral dose of a CB1 inhibitor, such as ANEB-001, and monitored for signs of improvement (heart rate, cognitive response, etc.).
- A human subject diagnosed or suspected of acute THC poisoning from overconsumption of cannabinoid products is treated by a clinician or first responder with a fast-acting nasal formulation comprising a CB1 inhibitor (e.g., ANEB-001) via nasal injector. The fast-acting nasal formulation is designed to provide effective amounts of the CB1 inhibitor in no more than 10 minutes.
- A patient admitted to the emergency room is diagnosed with acute THC poisoning from overconsumption of cannabinoid products, such as edibles. The patient is administered a formulation comprising a 75 mg oral dose of a CB1 inhibitor such as ANEB-001 and CBD (150 mg) and monitored for signs of improvement (heart rate, cognitive response, etc.).
- The description and examples presented above and the contents of the application define and describe examples of the many combinations, apparatus, and methods that can be produced or used according to the teachings here. None of the examples and no part of the description should be taken as a limitation on the scope of the inventions or of the meaning of the following claims.
Claims (57)
1. A method of using a pharmaceutical composition comprising a CB1 inhibitor, the method comprising administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has a known or suspected acute drug overdose reaction, wherein the CB1 inhibitor has the structure of formula (I):
or a pharmaceutically acceptable salt or prodrug thereof,
wherein
R1 is aryl or heteroaryl;
R2 is alkyl, aryl or heteroaryl;
R3 is alkyl, aryl, heteroaryl, NR9R10, OR15, or NR16C(O)R17;
Y is C═O, C═S, SO2, or (CR7R8)p;
R7 and R8 are independently selected from H and lower alkyl;
R9 is selected from H, alkyl, aryl, heteroaryl, and non-aromatic heterocyclic groups, or together with R10 forms a saturated 4, 5, 6, or 7 membered ring optionally containing an additional heteroatom selected from N and 0;
R10 is selected from H and lower alkyl, or together with R9 forms a saturated 4, 5, 6, or 7 membered ring optionally containing an additional heteroatom selected from N and 0;
R11 and R12 are independently selected from H and lower alkyl;
R15 is selected from alkyl and aryl;
R16 is selected from H and lower alkyl;
R17 is selected from alkyl, aryl and heteroaryl;
m is 1 or 2;
n is 1 or 2; and
p is 1, 2, 3 or 4.
2. The method of claim 1 , wherein m is 1 and n is 1.
3. The method of claim 1 or 2 , wherein R1 and R2 are independently aryl.
4. The method of any one of claims 1 -3 , wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [—CH—O—] group.
5. The method of any one of claims 1 -4 , wherein R11 and R12 are hydrogen.
6. The method of any one of claims 1 -5 , wherein R3 is NR9R10, and R9 and R10 are independently lower alkyl or hydrogen.
8. The method of claim 7 , wherein R1 and R2 are independently selected from a group of formula (II):
wherein
R4, R5, and R6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl,
NR14C(O)R19, NR14SO2R20, COOR19, OC(O)R20, CONR13R14 and SO2NR13R14,
R13 and R14 are independently selected from hydrogen and alkyl or form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O and S;
R19 is selected from H, alkyl, aryl and heteroaryl, and
R20 is selected from alkyl, aryl and heteroaryl.
9. The method of claim 8 , wherein at least one of R4, R5, and R6 are chloro or trifluoromethyl.
11. The method of any one of claims 1 -10 , wherein the patient shows signs of an acute cannabinoid overdose.
12. The method of any one of claims 1 -10 , wherein the patient shows signs of cannabinoid hyperemesis syndrome.
13. The method of any one of claims 1 -10 , wherein the method comprises treatment for drug overdose prior to treatment with the CB1 inhibitor.
14. The method of any one of claims 1 -10 , wherein the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic.
15. The method of claim 14 , wherein the prior treatment comprises one or more of orogastric lavage or whole bowel irrigation.
16. The method of any one of claims 1 -10 , wherein the method further comprises a diagnostic test prior to treatment with the CB1 inhibitor.
17. The method of claim 16 , wherein the diagnostic test is a blood test.
18. The method of claim 1 , wherein the patient has a cannabinoid plasma concentration of at least 50 μg/L.
19. The method of claim 18 , wherein the patient has a cannabinoid plasma concentration of at least 100 μg/L.
20. The method of claim 1 , wherein the patient has a cannabinoid plasma concentration of 50 g/L to 300 μg/L.
21. The method of any one of claims 1 -20 , wherein the pharmaceutical composition is prepared as an oral, sublingual, buccal, rectal, nasal, or parenteral dose.
22. The method of any one of claims 1 -20 , wherein the dose of the CB1 inhibitor is 1 mg to 200 mg.
23. The method of claim 22 , wherein the dose of the CB1 inhibitor is 25 mg to 200 mg.
24. The method of claim 22 , wherein the dose of the CB1 inhibitor is 50 mg to 200 mg.
25. The method of claim 22 wherein the dose of the CB1 inhibitor delivers a therapeutically effective amount of the CB1 inhibitor in no more than 10 minutes.
26. The method of claim 22 wherein the dose of the CB1 inhibitor delivers a therapeutically effective amount of the CB1 inhibitor in no more than 5 minutes.
27. The method of claim 22 wherein the amount of the CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within one hour after oral administration.
28. The method of claim 22 wherein the amount of the CB1 inhibitor in the bloodstream of the subject reaches at least 200 ng/mL within 30 minutes after oral administration.
29. The method of claim 22 , wherein the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 30 min.
30. The method of claim 22 , wherein the method is capable of ameliorating one or more symptoms of the acute drug overdose reaction in no more than 1 hour.
31. The method of any one of claims 1 -20 , wherein the CB1 inhibitor is formulated as an oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, suppository, or intranasal administration.
32. The method of any one of claims 1 -31 , further comprising administering a pharmaceutically acceptable alkaline agent.
33. The method of any one of claims 1 -32 , wherein the pharmaceutical composition is formulated to deliver an effective dose of the CB1 inhibitor in no more than 10 min.
34. A method of using a CB1 inhibitor as a pre-exposure prophylactic therapy comprising administering an effective amount of the CB1 inhibitor prior to exposure to a cannabinoid.
35. The method of claim 34 , wherein the cannabinoid is tetrahydrocannabinol.
36. The method of claim 34 or 35 wherein CB1 inhibitor is formulated for oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, suppository, or intranasal administration.
38. The method of any one of claims 1 -37 , wherein the excipient comprises a cyclodextrin.
39. The method of claim 34 , wherein the dose of the CB1 inhibitor is 1 mg to 200 mg.
40. A method of treating a patient suspected of a drug overdose comprising administering an effective amount of a CB1 inhibitor to a patient and monitoring the patient for reduced symptoms associated with overdose.
41. The method of claim 40 , wherein monitoring comprises monitoring heart rate or respiration.
43. The method of claim 42 , wherein the dose of the CB1 inhibitor is 1 mg to 200 mg.
44. The method of claim 42 , wherein the dose of the CB1 inhibitor is 25 mg to 200 mg.
45. The method of claim 42 , wherein the dose of the CB1 inhibitor is 50 mg to 200 mg.
46. An injectable composition for treating a suspected drug overdose, the composition comprising a CB1 inhibitor, an opioid antagonist, and a benzodiazepine antagonist.
47. The injectable composition of claim 46 , wherein the benzodiazepine antagonist is flumazenil.
48. The injectable composition of claim 46 or 47 , wherein the opioid antagonist is naloxone.
49. The injectable composition of any one of claims 46 -48 , wherein the injectable composition is formulated in a single dose injectable device.
51. The injectable composition of claim 50 , wherein the dose of the CB1 inhibitor is 1 mg to 200 mg.
52. A composition for treating a suspected drug overdose, the composition comprising a CB1 inhibitor and an anxiolytic agent.
53. The composition of claim 52 , wherein the anxiolytic agent is a cannabinoid.
54. The composition of claim 53 , wherein the cannabinoid is cannabidiol (CBD).
55. The composition of any one of claims 52 -54 , wherein composition is formulated for intranasal delivery.
57. The composition of claim 56 , wherein the dose of the CB1 inhibitor is 1 mg to 200 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/253,025 US20240000748A1 (en) | 2020-11-18 | 2021-11-17 | Formulations and methods for treating acute cannabinoid overdose |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063115487P | 2020-11-18 | 2020-11-18 | |
US18/253,025 US20240000748A1 (en) | 2020-11-18 | 2021-11-17 | Formulations and methods for treating acute cannabinoid overdose |
PCT/US2021/059747 WO2022109043A1 (en) | 2020-11-18 | 2021-11-17 | Formulations and methods for treating acute cannabinoid overdose |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240000748A1 true US20240000748A1 (en) | 2024-01-04 |
Family
ID=78007881
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/100,157 Active US11141404B1 (en) | 2020-11-18 | 2020-11-20 | Formulations and methods for treating acute cannabinoid overdose |
US17/484,593 Pending US20220151990A1 (en) | 2020-11-18 | 2021-09-24 | Formulations and methods for treating acute cannabinoid overdose |
US18/253,025 Pending US20240000748A1 (en) | 2020-11-18 | 2021-11-17 | Formulations and methods for treating acute cannabinoid overdose |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/100,157 Active US11141404B1 (en) | 2020-11-18 | 2020-11-20 | Formulations and methods for treating acute cannabinoid overdose |
US17/484,593 Pending US20220151990A1 (en) | 2020-11-18 | 2021-09-24 | Formulations and methods for treating acute cannabinoid overdose |
Country Status (6)
Country | Link |
---|---|
US (3) | US11141404B1 (en) |
EP (1) | EP4247362A1 (en) |
AU (1) | AU2021382590A1 (en) |
CA (1) | CA3198575A1 (en) |
IL (1) | IL302895A (en) |
WO (1) | WO2022109043A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11141404B1 (en) * | 2020-11-18 | 2021-10-12 | Anebulo Pharmaceuticals, Inc. | Formulations and methods for treating acute cannabinoid overdose |
CA3234167A1 (en) * | 2021-10-11 | 2023-04-20 | Joseph Fenton Lawler | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
WO2024073367A1 (en) * | 2022-09-26 | 2024-04-04 | Anebulo Pharmaceuticals, Inc. | Treatment of acute cannabinoid overdose |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1049672T3 (en) | 1998-01-23 | 2004-01-19 | Vernalis Res Ltd | Azetidine carboxamide derivatives for the treatment of CNS disorders |
GB9917386D0 (en) | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-II |
US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
WO2004096794A1 (en) | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs |
NZ543016A (en) * | 2003-05-01 | 2009-03-31 | Vernalis Res Ltd | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
US20060276452A1 (en) | 2003-05-01 | 2006-12-07 | Vernalis Research Limited | Use of azetidinecarboxamide derivatives in therapy |
WO2008024408A2 (en) * | 2006-08-22 | 2008-02-28 | Theraquest Biosciences, Inc. | Pharmaceutical formulations of cannabinoids for application to the skin and method of use |
MX2010009658A (en) | 2008-03-04 | 2010-09-30 | Vernalis R&D Ltd | Azetidine derivatives. |
FR2960875B1 (en) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2016014975A2 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
WO2018204689A1 (en) | 2017-05-04 | 2018-11-08 | The Board Of Regents Of The University Of Texas System | Methods of treating synthetic cannabinoid toxicity or overdose with rimonabant |
CA3122090A1 (en) | 2018-12-07 | 2020-06-11 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
US20200397749A1 (en) * | 2019-06-18 | 2020-12-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
US11141404B1 (en) * | 2020-11-18 | 2021-10-12 | Anebulo Pharmaceuticals, Inc. | Formulations and methods for treating acute cannabinoid overdose |
-
2020
- 2020-11-20 US US17/100,157 patent/US11141404B1/en active Active
-
2021
- 2021-09-24 US US17/484,593 patent/US20220151990A1/en active Pending
- 2021-11-17 CA CA3198575A patent/CA3198575A1/en active Pending
- 2021-11-17 WO PCT/US2021/059747 patent/WO2022109043A1/en unknown
- 2021-11-17 EP EP21895521.9A patent/EP4247362A1/en active Pending
- 2021-11-17 IL IL302895A patent/IL302895A/en unknown
- 2021-11-17 US US18/253,025 patent/US20240000748A1/en active Pending
- 2021-11-17 AU AU2021382590A patent/AU2021382590A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220151990A1 (en) | 2022-05-19 |
CA3198575A1 (en) | 2022-05-27 |
IL302895A (en) | 2023-07-01 |
AU2021382590A1 (en) | 2023-06-22 |
EP4247362A1 (en) | 2023-09-27 |
WO2022109043A1 (en) | 2022-05-27 |
US11141404B1 (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240000748A1 (en) | Formulations and methods for treating acute cannabinoid overdose | |
JP7090151B2 (en) | Methods for Administering Specific VMAT2 Inhibitors | |
TWI243678B (en) | A pharmaceutical composition for the treatment and/or prophylaxis of conditions characterized by altered bowel function and/or visceral pain in human or non-human mammals | |
EP3193907B1 (en) | Method of treating prader-willi syndrome | |
TW200815008A (en) | Method for enhancing cognitive function | |
Blough et al. | Alpha-ethyltryptamines as dual dopamine–serotonin releasers | |
EP4346788A2 (en) | Enantiomeric entactogen compositions and methods of their use | |
US20230265093A1 (en) | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) | |
NZ547919A (en) | Compounds for the sustained reduction of body weight | |
EP2716302A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
CA2425812C (en) | Treatment of oppositional defiant disorder and conduct disorder with 5-amino-4,5,6,7-tetrahydro-4-oxyindolones | |
WO2017041112A1 (en) | Ketamine and cytochrome p 450 inhibitor combinations | |
AU2017374450B2 (en) | Parenteral liquid preparation comprising carbamate compound | |
KR102141519B1 (en) | Treatment regimens | |
JP5299949B2 (en) | Cilostazol treatment for schizophrenia | |
KR20210141933A (en) | How to treat borderline personality disorder | |
KR101994596B1 (en) | Compositions and methods for treatment for neuropsychiatric disorders | |
JP2019524682A (en) | A vortioxetine regimen for rapid onset of antidepressant action | |
TW200914455A (en) | Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an analgesic effect, anti-allergic effect and histamine H1 receptor antagonism effect | |
EP4011366A1 (en) | Intraoral fast-disintegrating formulation containing hemp oil extract or hemp powder extract as raw material of formulation | |
JPH07503240A (en) | Use of 3-arylindole and 1-arylindazole derivatives for the treatment of psychosis | |
AU2007230977A1 (en) | Methods for treating cognitive and other disorders | |
WO2018116260A1 (en) | Pharmaceutical composition with anti-tubercular effect | |
JPH05507075A (en) | Benzylimidazole derivatives for anxiolytic and nootropic agents | |
EP3138560A1 (en) | Drug for treatment of tinnitus patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |